Abstract
In the past few decades, extensive research has been carried out to find novel biomarkers for various cancers. Cancer biomarkers play an important role in the screening, diagnosis, and posttreatment prognosis of patients in all the stages of the disease. The utilization of biomarkers is multifaceted; from screening healthy patients for risk assessment to timely diagnosis, accurate staging, patient stratification into risk groups, determining prognosis, and continued surveillance. Biomarkers play an indispensable role in both diagnosing and managing cancer treatment. Recent advancements in the field of precision medicine have led to the discovery of novel diagnostic and prognostic cancer biomarkers. Different protein-based, RNA, DNA, miRNA, and SNP-based biomarkers have been identified and developed as accurate, noninvasive, and cost-effective alternative towards managing different neoplastic diseases. The rapid progression in the field of diagnostic and prognostic biomarkers has led to the development of companion diagnostics and targeted therapies for the treatment of cancer patients, which has resulted in improved diagnosis and preventing unnecessary chemotherapy along with the associated toxicities.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
2006 update of ASCO recommendations for the use of tumor markers in gastrointestinal cancer (2006) J Oncol Pract 2(6):314–316. https://doi.org/10.1200/jop.2006.2.6.314
Abbaszadegan MR, Moaven O, Sima HR, Ghafarzadegan K, A’Rabi A, Forghani MN et al (2008) p16 promoter hypermethylation: a useful serum marker for early detection of gastric cancer. World J Gastroenterol 14(13):2055–2060. https://doi.org/10.3748/wjg.14.2055
Absmaier M, Napieralski R, Schuster T, Aubele M, Walch A, Magdolen V, Dorn J, Gross E, Harbeck N, Noske A, Kiechle M, Schmitt M (2018) PITX2 DNA-methylation predicts response to anthracycline-based adjuvant chemotherapy in triple-negative breast cancer patients. Int J Oncol 52(3):755–767. https://doi.org/10.3892/ijo.2018.4241
Albanell J, Andreu X, Calasanz MJ, Concha A, Corominas JM, García-Caballero T, López JA, López-Ríos F, Ramón y Cajal S, Vera-Sempere FJ, Colomer R, Martín M, Alba E, González-Martín A, Llombart A, Lluch A, Palacios J (2009) Guidelines for HER2 testing in breast cancer: a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM). Clin Transl Oncol 11(6):363–375. https://doi.org/10.1007/s12094-009-0370-6
Allin KH, Nordestgaard BG (2011) Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer. Crit Rev Clin Lab Sci 48(4):155–170. https://doi.org/10.3109/10408363.2011.599831
Alves Martins BA, de Bulhões GF, Cavalcanti IN, Martins MM, de Oliveira PG, Martins AMA (2019) Biomarkers in colorectal cancer: the role of translational proteomics research. Front Oncol 9:1284. https://doi.org/10.3389/fonc.2019.01284
Amiri-Dashatan N, Koushki M, Abbaszadeh H-A, Rostami-Nejad M, Rezaei-Tavirani M (2018) Proteomics applications in health: biomarker and drug discovery and food industry. Iran J Pharm Res 17(4):1523–1536
An SJ, Chen ZH, Su J, Zhang XC, Zhong WZ, Yang JJ, Zhou Q, Yang XN, Huang L, Guan JL, Nie Q, Yan HH, Mok TS, Wu YL (2012) Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status. PLoS One 7(6):e40109. https://doi.org/10.1371/journal.pone.0040109
Anderson WF, Chatterjee N, Ershler WB, Brawley OW (2002) Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat 76(1):27–36. https://doi.org/10.1023/a:1020299707510
Aoki T, Steidl C (2018) Novel biomarker approaches in classic Hodgkin lymphoma. Cancer 24(5):206–214
Arancio W, Belmonte B, Castiglia M, Di Napoli A, Tripodo C (2017) Tissue versus liquid biopsy: opposite or complementary? In: Russo A, Giordano A, Rolfo C (eds) Liquid biopsy in cancer patients: the hand lens for tumor evolution, e-book. Springer International Publishing, Cham. https://doi.org/10.1007/978-3-319-55661-1_4
Arnold M, Abnet CC, Neale RE, Vignat J, Giovannucci EL, McGlynn KA, Bray F (2020) Global burden of 5 major types of gastrointestinal cancer. Gastroenterology 159(1):335–349.e315. https://doi.org/10.1053/j.gastro.2020.02.068
Arosio P, Yokota M, Drysdale JW (1976) Structural and immunological relationships of isoferritins in normal and malignant cells. Cancer Res 36(5):1735–1739
Asgari-Karchekani S, Karimian M, Mazoochi T, Taheri MA, Khamehchian T (2020) CDX2 protein expression in colorectal cancer and its correlation with clinical and pathological characteristics, prognosis, and survival rate of patients. J Gastrointest Cancer 51(3):844–849. https://doi.org/10.1007/s12029-019-00314-w
el Atiq F, Garrouste F, Remacle-Bonnet M, Sastre B, Pommier G (1994) Alterations in serum levels of insulin-like growth factors and insulin-like growth-factor-binding proteins in patients with colorectal cancer. Int J Cancer 57(4):491–497. https://doi.org/10.1002/ijc.2910570409
Badgwell D, Lu Z, Cole L, Fritsche H, Atkinson EN, Somers E, Allard J, Moore RG, Lu KH, Bast RC Jr (2007) Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment. Gynecol Oncol 106(3):490–497. https://doi.org/10.1016/j.ygyno.2007.04.022
Balasenthil S, Huang Y, Liu S, Marsh T, Chen J, Stass SA et al (2017) A plasma biomarker panel to identify surgically resectable early-stage pancreatic cancer. J Natl Cancer Inst 109(8):djw341. https://doi.org/10.1093/jnci/djw341
Baldwin RL, Nemeth E, Tran H, Shvartsman H, Cass I, Narod S, Karlan BY (2000) BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study. Cancer Res 60(19):5329–5333
Bantia S, Parker C, Upshaw R, Cunningham A, Kotian P, Kilpatrick JM et al (2010) Potent orally bioavailable purine nucleoside phosphorylase inhibitor BCX-4208 induces apoptosis in B- and T-lymphocytes—a novel treatment approach for autoimmune diseases, organ transplantation and hematologic malignancies. Int Immunopharmacol 10(7):784–790. https://doi.org/10.1016/j.intimp.2010.04.009
Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM (2003) Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 21(10):1973–1979. https://doi.org/10.1200/JCO.2003.09.099
Bast RC Jr, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC (1981) Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 68(5):1331–1337. https://doi.org/10.1172/jci110380
Bast RC, Xu F-J, Yu Y-H, Barnhill S, Zhang Z, Mills GB (1998) CA 125: the past and the future. Int J Biol Markers 13(4):179–187. https://doi.org/10.1177/172460089801300402
Bast RC, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J, Baggerly KA, Atkinson EN, Skates S, Zhang Z, Lokshin A, Menon U, Jacobs I, Lu K (2005) New tumor markers: CA125 and beyond. Int J Gynecol Cancer 15(s3):274–281. https://doi.org/10.1111/j.1525-1438.2005.00441.x
Baylin SB, Herman JG (2000) DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 16(4):168–174. https://doi.org/10.1016/s0168-9525(99)01971-x
Bayrak R, Yenidünya S, Haltas H (2011) Cytokeratin 7 and cytokeratin 20 expression in colorectal adenocarcinomas. Pathol Res Pract 207(3):156–160. https://doi.org/10.1016/j.prp.2010.12.005
Benchikh A, Savage C, Cronin A, Salama G, Villers A, Lilja H, Vickers A (2010) A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: an independent validation study from the European Randomized Study of Prostate Cancer screening. France BMC Cancer 10:635. https://doi.org/10.1186/1471-2407-10-635
Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT, Massion PP, Siwak-Tapp C, Gonzalez A, Fang R, Mark EJ, Batten JM, Chen H, Wilner KD, Kwak EL, Clark JW, Carbone DP, Ji H, Engelman JA, Mino-Kenudson M et al (2012) ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 30(8):863–870. https://doi.org/10.1200/JCO.2011.35.6345
Bian T, Zhao J, Feng J, Zhang Q, Qian L, Liu J et al (2017) Combination of cadherin-17 and SATB homeobox 2 serves as potential optimal makers for the differential diagnosis of pulmonary enteric adenocarcinoma and metastatic colorectal adenocarcinoma. Oncotarget 8(38):63442–63452. https://doi.org/10.18632/oncotarget.18828
Bibikova M, Lin Z, Zhou L, Chudin E, Garcia EW, Wu B, Doucet D, Thomas NJ, Wang Y, Vollmer E, Goldmann T, Seifart C, Jiang W, Barker DL, Chee MS, Floros J, Fan JB (2006) High-throughput DNA methylation profiling using universal bead arrays. Genome Res 16(3):383–393. https://doi.org/10.1101/gr.441070
Blank S, Knebel P, Haag G-M, Bruckner T, Klaiber U, Burian M et al (2016) Immediate tumor resection in patients with locally advanced gastro-esophageal adenocarcinoma with nonresponse to chemotherapy after 4 weeks of treatment versus resection after completion of chemotherapy (OPTITREAT trial, DRKS00004668): study protocol for a randomized controlled pilot trial. Pilot Feasibility Stud 2:18–18. https://doi.org/10.1186/s40814-016-0059-x
Blumenthal RD, Leon E, Hansen HJ, Goldenberg DM (2007) Expression patterns of CEACAM5 and CEACAM6 in primary and metastatic cancers. BMC Cancer 7:2. https://doi.org/10.1186/1471-2407-7-2
Boku N, Ohtsu A, Nagashima F, Shirao K, Koizumi W (2007) Relationship between expression of vascular endothelial growth factor in tumor tissue from gastric cancers and chemotherapy effects: comparison between S-1 alone and the combination of S-1 plus CDDP. Jpn J Clin Oncol 37(7):509–514. https://doi.org/10.1093/jjco/hym057
Brown LF, Papadopoulos-Sergiou A, Berse B, Manseau EJ, Tognazzi K, Perruzzi CA, Dvorak HF, Senger DR (1994) Osteopontin expression and distribution in human carcinomas. Am J Pathol 145(3):610–623
Burton CH, Scott D, Kirkwood AA et al (2017) Application of a gene expression–based model in combination with FDG-PET imaging to predict treatment response in advanced Hodgkin lymphoma in the RATHL Study (CRUK/07/033). Hematol Oncol 35:91–92
Butters O, Young K, Cunningham D, Chau I, Starling N (2019) Targeting vascular endothelial growth factor in oesophagogastric cancer: a review of progress to date and immunotherapy combination strategies. Front Oncol 9:618. https://doi.org/10.3389/fonc.2019.00618
Buzdar AU, Vergote I, Sainsbury R (2004) The impact of hormone receptor status on the clinical efficacy of the new-generation aromatase inhibitors: a review of data from firstline metastatic disease trials in postmenopausal women. Breast J 10(3):211–217. https://doi.org/10.1111/j.1075-122X.2004.21320.x. Cancer journal (Sudbury, Mass.), 24(5), 206–214
Calanzani N, Druce PE, Snudden C, Milley KM, Boscott R, Behiyat D et al (2021) Identifying novel biomarkers ready for evaluation in low-prevalence populations for the early detection of upper gastrointestinal cancers: a systematic review. Adv Ther 38(2):793–834. https://doi.org/10.1007/s12325-020-01571-z
Cao S, Zhan Y, Dong Y (2016) Emerging data on androgen receptor splice variants in prostate cancer. Endocr Relat Cancer 23(12):T199–T210. https://doi.org/10.1530/erc-16-0298
Caputo F, Santini C, Bardasi C, Cerma K, Casadei-Gardini A, Spallanzani A et al (2019) BRAF-mutated colorectal cancer: clinical and molecular insights. Int J Mol Sci 20(21):5369. https://doi.org/10.3390/ijms20215369
Carethers JM, Jung BH (2015) Genetics and genetic biomarkers in sporadic colorectal cancer. Gastroenterology 149(5):1177–1190.e1173. https://doi.org/10.1053/j.gastro.2015.06.047
Cecchi F, Rabe DC, Bottaro DP (2012) Targeting the HGF/Met signaling pathway in cancer therapy. Expert Opin Ther Targets 16(6):553–572. https://doi.org/10.1517/14728222.2012.680957
Cedolini C, Bertozzi S, Londero AP, Bernardi S, Seriau L, Concina S, Cattin F, Risaliti A (2014) Type of breast cancer diagnosis, screening, and survival. Clin Breast Cancer 14(4):235–240. https://doi.org/10.1016/j.clbc.2014.02.004
Cescon DW, Bradbury PA, Asomaning K, Hopkins J, Zhai R, Zhou W et al (2009) p53 Arg72Pro and MDM2 T309G polymorphisms, histology, and esophageal cancer prognosis. Clin Cancer Res 15(9):3103–3109. https://doi.org/10.1158/1078-0432.CCR-08-3120
Chan DSY, Twine CP, Lewis WG (2012) Systematic review and meta-analysis of the influence of HER2 expression and amplification in operable oesophageal cancer. J Gastrointest Surg 16(10):1821–1829. https://doi.org/10.1007/s11605-012-1979-2
Chand M, Keller DS, Mirnezami R, Bullock M, Bhangu A, Moran B et al (2018) Novel biomarkers for patient stratification in colorectal cancer: a review of definitions, emerging concepts, and data. World J Gastrointest Oncol 10(7):145–158. https://doi.org/10.4251/wjgo.v10.i7.145
Chaudhry A, Aniol H, Shegos C (2020). https://www.consultant360.com/article/consultant360/congenital-hypothyroidism-due-thyroid-agenesis. Consultant. https://doi.org/10.25270/con.2020.05.00011
Chen FJ, Sun M, Li SQ, Wu QQ, Ji L, Liu ZL et al (2013a) Upregulation of the long non-coding RNA HOTAIR promotes esophageal squamous cell carcinoma metastasis and poor prognosis. Mol Carcinog 52(11):908–915. https://doi.org/10.1002/mc.21944
Chen L, Li G, Li J, Fan C, Xu J, Wu B et al (2013b) Correlation between expressions of ERCC1/TS mRNA and effects of gastric cancer to chemotherapy in the short term. Cancer Chemother Pharmacol 71(4):921–928. https://doi.org/10.1007/s00280-013-2083-3
Chen G, Peng J, Zhu W, Tao G, Song Y, Zhou X, Wang W (2014) Combined downregulation of microRNA-133a and microRNA-133b predicts chemosensitivity of patients with esophageal squamous cell carcinoma undergoing paclitaxel-based chemotherapy. Med Oncol 31(11):263. https://doi.org/10.1007/s12032-014-0263-6
Chen L-T, Oh D-Y, Ryu M-H, Yeh K-H, Yeo W, Carlesi R et al (2017) Anti-angiogenic therapy in patients with advanced gastric and gastroesophageal junction cancer: a systematic review. Cancer Res Treat 49(4):851–868. https://doi.org/10.4143/crt.2016.176
Choi Y, Sateia HF, Peairs KS, Stewart RW (2017) Screening for colorectal cancer. Semin Oncol 44(1):34–44. https://doi.org/10.1053/j.seminoncol.2017.02.002
Chromek M, Tullus K, Lundahl J, Brauner A (2004) Tissue inhibitor of metalloproteinase 1 activates normal human granulocytes, protects them from apoptosis, and blocks their transmigration during inflammation. Infect Immun 72(1):82–88. https://doi.org/10.1128/iai.72.1.82-88.2004
Chu CS, Rubin SC (2006) Screening for ovarian cancer in the general population. Best Pract Res Clin Obstet Gynaecol 20(2):307–320. https://doi.org/10.1016/j.bpobgyn.2005.10.012
Cizkova M, Dujaric ME, Lehmann-Che J, Scott V, Tembo O, Asselain B, Pierga JY, Marty M, de Cremoux P, Spyratos F, Bieche I (2013) Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab. Br J Cancer 108(9):1807–1809. https://doi.org/10.1038/bjc.2013.164
Colaković S, Lukiç V, Mitroviç L, Jeliç S, Susnjar S, Marinkoviç J (2000) Prognostic value of CA125 kinetics and half-life in advanced ovarian cancer. Int J Biol Markers 15(2):147–152
Colozza M, Azambuja E, Cardoso F, Sotiriou C, Larsimont D, Piccart MJ (2005) Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? Ann Oncol 16(11):1723–1739. https://doi.org/10.1093/annonc/mdi352
Condrat CE, Thompson DC, Barbu MG, Bugnar OL, Boboc A, Cretoiu D et al (2020) miRNAs as biomarkers in disease: latest findings regarding their role in diagnosis and prognosis. Cells 9(2):276. https://doi.org/10.3390/cells9020276
Corcoran RB, Contino G, Deshpande V, Tzatsos A, Conrad C, Benes CH et al (2011) STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. Cancer Res 71(14):5020–5029. https://doi.org/10.1158/0008-5472.can-11-0908
Costello LC, Levy BA, Desouki MM, Zou J, Bagasra O, Johnson LA et al (2011) Decreased zinc and downregulation of ZIP3 zinc uptake transporter in the development of pancreatic adenocarcinoma. Cancer Biol Ther 12(4):297–303. https://doi.org/10.4161/cbt.12.4.16356
Couch G, Redman JE, Wernisch L, Newton R, Malhotra S, Dawsey SM et al (2016) The discovery and validation of biomarkers for the diagnosis of esophageal squamous dysplasia and squamous cell carcinoma. Cancer Prev Res (Phila) 9(7):558–566. https://doi.org/10.1158/1940-6207.capr-15-0379
Creed J, Klotz L, Harbottle A, Maggrah A, Reguly B, George A, Gnanapragasm V (2017) A single mitochondrial DNA deletion accurately detects significant prostate cancer in men in the PSA ‘grey zone’. World J Urol 36(3):341–348. https://doi.org/10.1007/s00345-017-2152-z
Crnogorac-Jurcevic T, Chelala C, Barry S, Harada T, Bhakta V, Lattimore S et al (2013) Molecular analysis of precursor lesions in familial pancreatic cancer. PLoS One 8(1):e54830. https://doi.org/10.1371/journal.pone.0054830
Cui M, Wang H, Yao X, Zhang D, Xie Y, Cui R, Zhang X (2019) Circulating MicroRNAs in cancer: potential and challenge. Front Genet 10:626. https://doi.org/10.3389/fgene.2019.00626
Darson MF, Pacelli A, Roche P, Rittenhouse HG, Wolfert RL, Saeid MS, Young CY, Klee GG, Tindall DJ, Bostwick DG (1999) Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases. Urology 53(5):939–944. https://doi.org/10.1016/s0090-4295(98)00637-2
Das M, Sharma SK, Sekhon GS, Saikia BJ, Mahanta J, Phukan RK (2014) Promoter methylation of MGMT gene in serum of patients with esophageal squamous cell carcinoma in North East India. Asian Pac J Cancer Prev 15(22):9955–9960. https://doi.org/10.7314/apjcp.2014.15.22.9955
Dasgupta A, Lim AR, Ghajar CM (2017) Circulating and disseminated tumor cells: harbingers or initiators of metastasis? Mol Oncol 11(1):40–61. https://doi.org/10.1002/1878-0261.12022
Delaney LJ, Machado P, Torkzaban M, Lyshchik A, Wessner CE, Kim C, Rosenblum N, Richard S, Wallace K, Forsberg F (2020) Characterization of adnexal masses using contrast-enhanced subharmonic imaging: a pilot study. J Ultrasound Med 39(5):977–985. https://doi.org/10.1002/jum.15183
Desotelle J, Truong M, Ewald J, Weeratunga P, Yang B, Huang W, Jarrard D (2013) CpG Island hypermethylation frequently silences FILIP1L isoform 2 expression in prostate cancer. J Urol 189(1):329–335. https://doi.org/10.1016/j.juro.2012.08.188
Di Gangi IM, Mazza T, Fontana A, Copetti M, Fusilli C, Ippolito A et al (2016) Metabolomic profile in pancreatic cancer patients: a consensus-based approach to identify highly discriminating metabolites. Oncotarget 7(5):5815–5829. https://doi.org/10.18632/oncotarget.6808
Ding H, Wu T (2018) Insulin-like growth factor binding proteins in autoimmune diseases. Front Endocrinol 9:499. https://doi.org/10.3389/fendo.2018.00499
Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, Sougnez C, Greulich H, Muzny DM, Morgan MB, Fulton L, Fulton RS, Zhang Q, Wendl MC, Lawrence MS, Larson DE, Chen K, Dooling DJ, Sabo A, Hawes AC et al (2008) Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455(7216):1069–1075. https://doi.org/10.1038/nature07423
Dogan S, Shen R, Ang DC, Johnson ML, D’Angelo SP, Paik PK, Brzostowski EB, Riely GJ, Kris MG, Zakowski MF, Ladanyi M (2012) Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers. Clin Cancer Res 18(22):6169–6177. https://doi.org/10.1158/1078-0432.CCR-11-3265
Doi T, Muro K, Boku N, Yamada Y, Nishina T, Takiuchi H et al (2010) Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer. J Clin Oncol 28(11):1904–1910. https://doi.org/10.1200/JCO.2009.26.2923
Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, A’Hern R, Salter J, Detre S, Conteduca V, Wetterskog D, Sharabiani M, Grande E, Fernandez-Perez M, Jayaram A et al (2017) Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study. Ann Oncol 28(7):1508–1516. https://doi.org/10.1093/annonc/mdx155
Dragomir A, de Wit M, Johansson C, Uhlen M, Pontén F (2014) The role of SATB2 as a diagnostic marker for tumors of colorectal origin: results of a pathology-based clinical prospective study. Am J Clin Pathol 141(5):630–638. https://doi.org/10.1309/ajcpww2urz9jkqju
Driul L, Bernardi S, Bertozzi S, Schiavon M, Londero AP, Petri R (2013) New surgical trends in breast cancer treatment: conservative interventions and oncoplastic breast surgery. Minerva Ginecol 65(3):289–296
Dudley JC, Lin MT, Le DT, Eshleman JR (2016) Microsatellite instability as a biomarker for PD-1 blockade. Clin Cancer Res 22(4):813–820. https://doi.org/10.1158/1078-0432.ccr-15-1678
Duffy MJ, McGowan PM, Harbeck N, Thomssen C, Schmitt M (2014) uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies. Breast Cancer Res 16(4):428. Published 2014 Aug 22. https://doi.org/10.1186/s13058-014-0428-4
Duggan SP, Garry C, Behan FM, Phipps S, Kudo H, Kirca M et al (2018) siRNA library screening identifies a druggable immune-signature driving esophageal adenocarcinoma cell growth. Cell Mol Gastroenterol Hepatol 5(4):569–590. https://doi.org/10.1016/j.jcmgh.2018.01.012
Early Breast Cancer Trialists’ Collaborative Group (1988) Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. N Engl J Med 319(26):1681–1692. https://doi.org/10.1056/NEJM198812293192601
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet (London, England) 365(9472):1687–1717. https://doi.org/10.1016/S0140-6736(05)66544-0
Edkins S, O’Meara S, Parker A, Stevens C, Reis M, Jones S, Greenman C, Davies H, Dalgliesh G, Forbes S, Hunter C, Smith R, Stephens P, Goldstraw P, Nicholson A, Chan TL, Velculescu VE, Yuen ST, Leung SY, Stratton MR et al (2006) Recurrent KRAS codon 146 mutations in human colorectal cancer. Cancer Biol Ther 5(8):928–932. https://doi.org/10.4161/cbt.5.8.3251
Eeles R, Raghallaigh H (2018) Men with a susceptibility to prostate cancer and the role of genetic based screening. Transl Androl Urol 7(1):61–69. https://doi.org/10.21037/tau.2017.12.30
El Sherbini MA, Sallam MM, Shaban EA, El-Shalakany AH (2011) Diagnostic value of serum kallikrein-related peptidases 6 and 10 versus CA125 in ovarian cancer. Int J Gynecol Cancer 21(4):625–632. https://doi.org/10.1097/IGC.0b013e31821283c3
Elledge RM, Fuqua SA, Clark GM, Pujol P, Allred DC, McGuire WL (1993) Prognostic significance of p53 gene alterations in node-negative breast cancer. Breast Cancer Res Treat 26(3):225–235. https://doi.org/10.1007/BF00665800
Ellis MJ, Suman VJ, Hoog J, Lin L, Snider J, Prat A, Parker JS, Luo J, DeSchryver K, Allred DC, Esserman LJ, Unzeitig GW, Margenthaler J, Babiera GV, Marcom PK, Guenther JM, Watson MA, Leitch M, Hunt K, Olson JA (2011) Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype—ACOSOG Z1031. J Clin Oncol 29(17):2342–2349. https://doi.org/10.1200/JCO.2010.31.6950
Esserman LJ, Thompson IM Jr, Reid B (2013) Overdiagnosis and overtreatment in cancer: an opportunity for improvement. JAMA 310(8):797–798. https://doi.org/10.1001/jama.2013.108415
Fang C, Zan J, Yue B, Liu C, He C, Yan D (2017) Long non-coding ribonucleic acid zinc finger antisense 1 promotes the progression of colonic cancer by modulating ZEB1 expression. J Gastroenterol Hepatol 32(6):1204–1211. https://doi.org/10.1111/jgh.13646
Fareed KR, Al-Attar A, Soomro IN, Kaye PV, Patel J, Lobo DN et al (2010) Tumour regression and ERCC1 nuclear protein expression predict clinical outcome in patients with gastro-oesophageal cancer treated with neoadjuvant chemotherapy. Br J Cancer 102(11):1600–1607. https://doi.org/10.1038/sj.bjc.6605686
Farina L, Rezzonico F, Spina F et al (2014) Serum thymus and activationregulated chemokine level monitoring may predict disease relapse detected by PET scan after reduced-intensity allogeneic stem cell transplantation in patients with Hodgkin lymphoma. Biol Blood Marrow Transplant 20:1982–1988
Fasching PA, Heusinger K, Haeberle L, Niklos M, Hein A, Bayer CM, Rauh C, SchulzWendtland R, Bani MR, Schrauder M, Kahmann L, Lux MP, Strehl JD, Hartmann A, Dimmler A, Beckmann MW, Wachter DL (2011) Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. BMC Cancer 11:486. https://doi.org/10.1186/1471-2407-11-486
Fernandez-Garcia D, Hills A, Page K, Hastings RK, Toghill B, Goddard KS et al (2019) Plasma cell-free DNA (cfDNA) as a predictive and prognostic marker in patients with metastatic breast cancer. Breast Cancer Res 21(1):149. https://doi.org/10.1186/s13058-019-1235-8
Fisher B, Redmond C, Fisher ER, Caplan R (1988) Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. J Clin Oncol 6(7):1076–1087. https://doi.org/10.1200/JCO.1988.6.7.1076
Foijer F, Draviam VM, Sorger PK (2008) Studying chromosome instability in the mouse. Biochim Biophys Acta 1786(1):73–82. https://doi.org/10.1016/j.bbcan.2008.07.004
Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230(3):309–318; discussion 318–321. https://doi.org/10.1097/00000658-199,909,000-00004
Forghanifard MM, Vahid EE, Dadkhah E, Gholamin M, Noghabi SB, Ghahraman M et al (2016) Loss of heterozygosity and microsatellite instability as predictive markers among Iranian esophageal cancer patients. Iran J Basic Med Sci 19(7):726–733
Fredsøe J, Rasmussen A, Thomsen AR, Mouritzen P, Høyer S, Borre M, Ørntoft TF, Sørensen KD (2018) Diagnostic and prognostic microRNA biomarkers for prostate cancer in cell-free urine. Eur Urol Focus 4(6):825–833. https://doi.org/10.1016/j.euf.2017.02.018
Frühwald MC (2003) DNA methylation patterns in cancer: novel prognostic indicators? Am J Pharmacogenomics 3(4):245–260. https://doi.org/10.2165/00129785-200303040-00003
Fujimoto J, Wistuba II (2014) Current concepts on the molecular pathology of non-small cell lung carcinoma. Semin Diagn Pathol 31(4):306–313. https://doi.org/10.1053/j.semdp.2014.06.008
Fujishima H, Fumoto S, Shibata T, Nishiki K, Tsukamoto Y, Etoh T et al (2017) A 17-molecule set as a predictor of complete response to neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in esophageal cancer. PLoS One 12(11):e0188098. https://doi.org/10.1371/journal.pone.0188098
Gabriel E, Bagaria SP (2018) Assessing the impact of circulating tumor DNA (ctDNA) in patients with colorectal cancer: separating fact from fiction. Front Oncol 8:297. https://doi.org/10.3389/fonc.2018.00297
Gadomska H, Grzechocińska B, Janecki J, Nowicka G, Powolny M, Marianowski L (2005) Serum lipids concentration in women with benign and malignant ovarian tumours. Eur J Obstet Gynecol Reprod Biol 120(1):87–90. https://doi.org/10.1016/j.ejogrb.2004.02.045
Gallamini A, Hutchings M, Rigacci L et al (2007) Early interim 2-[18F]fluoro-2- deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 25:3746–3752
Gambhir S, Vyas D, Hollis M, Aekka A, Vyas A (2015) Nuclear factor kappa B role in inflammation associated gastrointestinal malignancies. World J Gastroenterol 21(11):3174–3183. https://doi.org/10.3748/wjg.v21.i11.3174
Ge C, Wang F, Cui C, Su X, To KKW, Wang X et al (2018) PCI29732, a Bruton’s tyrosine kinase inhibitor, enhanced the efficacy of conventional chemotherapeutic agents in ABCG2-overexpressing cancer cells. Cell Physiol Biochem 48(6):2302–2317. https://doi.org/10.1159/000492647
Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E et al (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366(10):883–892. https://doi.org/10.1056/NEJMoa1113205
German S, Aslam HM, Saleem S, Raees A, Anum T, Alvi AA, Haseeb A (2013) Carcinogenesis of PIK3CA. Heredit Cancer Clin Pract 11(1):5. https://doi.org/10.1186/1897-4287-11-5
Ghosh RK, Pandey T, Dey P (2019) Liquid biopsy: a new avenue in pathology. Cytopathology 30(2):138–143
Goldberg R, Meirovitz A, Abecassis A, Hermano E, Rubinstein AM, Nahmias D et al (2019) Regulation of heparanase in diabetes-associated pancreatic carcinoma. Front Oncol 9:1405. https://doi.org/10.3389/fonc.2019.01405
Golyan FF, Druley TE, Abbaszadegan MR (2020) Whole-exome sequencing of familial esophageal squamous cell carcinoma identified rare pathogenic variants in new predisposition genes. Clin Transl Oncol 22(5):681–693. https://doi.org/10.1007/s12094-019-02174-z
Gong FF, Lu SS, Hu CY, Qian ZZ, Feng F, Wu YL et al (2014) Cytochrome P450 1A1 (CYP1A1) polymorphism and susceptibility to esophageal cancer: an updated meta-analysis of 27 studies. Tumour Biol 35(10):10351–10361. https://doi.org/10.1007/s13277-014-2341-y
Gong W, Tian M, Qiu H, Yang Z (2017) Elevated serum level of lncRNA-HIF1A-AS1 as a novel diagnostic predictor for worse prognosis in colorectal carcinoma. Cancer Biomark 20(4):417–424. https://doi.org/10.3233/cbm-170,179
Granville CA, Dennis PA (2005) An overview of lung cancer genomics and proteomics. Am J Respir Cell Mol Biol 32(3):169–176. https://doi.org/10.1165/rcmb.F290
Grover PK, Cummins AG, Price TJ, Roberts-Thomson IC, Hardingham JE (2014) Circulating tumour cells: the evolving concept and the inadequacy of their enrichment by EpCAM-based methodology for basic and clinical cancer research. Ann Oncol 25(8):1506–1516. https://doi.org/10.1093/annonc/mdu018
Guerrero CLH, Yamashita Y, Miyara M, Imaizumi N, Kato M, Sakihama S et al (2020) Proteomic profiling of HTLV-1 carriers and ATL patients reveals sTNFR2 as a novel diagnostic biomarker for acute ATL. Blood Adv 4(6):1062–1071
Guppy AE, Rustin GJS (2002) CA125 response: can it replace the traditional response criteria in ovarian cancer? Oncologist 7(5):437–443. https://doi.org/10.1634/theoncologist.7-5-437
Gzil A, Zarębska I, Bursiewicz W, Antosik P, Grzanka D, Szylberg Ł (2019) Markers of pancreatic cancer stem cells and their clinical and therapeutic implications. Mol Biol Rep 46(6):6629–6645. https://doi.org/10.1007/s11033-019-05058-1
Hammerman PS, Sos ML, Ramos AH, Xu C, Dutt A, Zhou W, Brace LE, Woods BA, Lin W, Zhang J, Deng X, Lim SM, Heynck S, Peifer M, Simard JR, Lawrence MS, Onofrio RC, Salvesen HB, Seidel D, Zander T et al (2011) Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov 1(1):78–89. https://doi.org/10.1158/2159-8274.CD-11-0005
Hao XD, Yang Y, Song X, Zhao XK, Wang LD, He JD et al (2013) Correlation of telomere length shortening with TP53 somatic mutations, polymorphisms and allelic loss in breast tumors and esophageal cancer. Oncol Rep 29(1):226–236. https://doi.org/10.3892/or.2012.2098
Harpole DH Jr, Moore MB, Herndon JE II, Aloia T, D’Amico TA, Sporn T et al (2001) The prognostic value of molecular marker analysis in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res 7(3):562–569
Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC Jr, American Society of Clinical Oncology (2007) American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25(33):5287–5312. https://doi.org/10.1200/JCO.2007.14.2364
Harris LN, Ismaila N, McShane LM, Andre F, Collyar DE, Gonzalez-Angulo AM, Hammond EH, Kuderer NM, Liu MC, Mennel RG, Van Poznak C, Bast RC, Hayes DF, American Society of Clinical Oncology (2016) Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 34(10):1134–1150. https://doi.org/10.1200/JCO.2015.65.2289
Hassan R, Ho M (2008) Mesothelin targeted cancer immunotherapy. Eur J Cancer (Oxford, England: 1990) 44(1):46–53. https://doi.org/10.1016/j.ejca.2007.08.028
Hassan R, Kreitman RJ, Pastan I, Willingham MC (2005) Localization of mesothelin in epithelial ovarian cancer. Appl Immunohistochem Mol Morphol 13(3):243–247. https://doi.org/10.1097/01.pai.00000141545.36485.d6
Heidarpour M, Taheri M, Akhavan A, Goli P, Kefayat A (2020) Investigation of HER-2 expression an its correlation with clinicopathological parameters and overall survival of esophageal squamous cell carcinoma patients. Iranian J Pathol 15(4):274–281. https://doi.org/10.30699/IJP.2020.113829.2235
Heidemann J, Binion D, Domschke W, Kucharzik T (2006) Antiangiogenic therapy in human gastrointestinal malignancies. Gut 55:1497–1511. https://doi.org/10.1136/gut.2005.088229
Herman JG, Baylin SB (2003) Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349(21):2042–2054. https://doi.org/10.1056/NEJMra02307
Hilliard TS (2018) The impact of mesothelin in the ovarian cancer tumor microenvironment. Cancer 10(9):277. https://doi.org/10.3390/cancers10090277
Hiyoshi Y, Watanabe M (2015) MicroRNAs in gastrointestinal cancer: a novel biomarker and its clinical application. J Cancer Metastasis Treat 1:144–155. https://doi.org/10.4103/2394-4722.161617
Hong L, Han Y, Zhang H, Fan D (2015) Prognostic markers in esophageal cancer: from basic research to clinical use. Expert Rev Gastroenterol Hepatol 9(7):887–889. https://doi.org/10.1586/17474124.2015.1041507
Hortobagyi GN, Holmes FA (1996) Single-agent paclitaxel for the treatment of breast cancer: an overview. Semin Oncol 23(1 Suppl 1):4–9. https://doi.org/10.1002/1097-0142(197508)36:2+<638::aid-cncr2820360805>3.0.co;2-
Hsueh CT, Liu D, Wang H (2013) Novel biomarkers for diagnosis, prognosis, targeted therapy and clinical trials. Biomark Res 1:1. https://doi.org/10.1186/2050-7771-1-1
Hua S, Kittler R, White KP (2009) Genomic antagonism between retinoic acid and estrogen signaling in breast cancer. Cell 137(7):1259–1271. https://doi.org/10.1016/j.cell.2009.04.043
Huang SM, Harari PM (1999) Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results. Invest New Drugs 17(3):259–269
Huang C, Yu Z, Yang H, Lin Y (2016a) Increased MALAT1 expression predicts poor prognosis in esophageal cancer patients. Biomed Pharmacother 83:8–13. https://doi.org/10.1016/j.biopha.2016.05.044
Huang T, Kang W, Zhang B, Wu F, Dong Y, Tong JHM et al (2016b) miR-508-3p concordantly silences NFKB1 and RELA to inactivate canonical NF-κB signaling in gastric carcinogenesis. Mol Cancer 15(1):9. https://doi.org/10.1186/s12943-016-0493-7
Huang WL, Chen YL, Yang SC, Ho CL, Wei F, Wong DT et al (2017a) Liquid biopsy genotyping in lung cancer: ready for clinical utility? Oncotarget 8(11):18590–18608. https://doi.org/10.18632/oncotarget.14613
Huang X, Liu C, Cui Y, Zhang H, Liu Y, Zhou X, Luo J (2017b) Association between XRCC1 and ERCC1 single-nucleotide polymorphisms and the efficacy of concurrent radiochemotherapy in patients with esophageal squamous cell carcinoma. Oncol Lett 13(2):704–714. https://doi.org/10.3892/ol.2016.5496
Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, Taccioli C, Volinia S, Liu CG, Alder H, Calin GA, Ménard S, Croce CM (2007) MicroRNA signatures in human ovarian cancer. Cancer Res 67(18):8699–8707. https://doi.org/10.1158/0008-5472.CAN-07-1936
Irwin RE, Thursby S-J, Ondičová M, Pentieva K, McNulty H, Richmond RC et al (2019) A randomized controlled trial of folic acid intervention in pregnancy highlights a putative methylation-regulated control element at ZFP57. Clin Epigenetics 11(1):31. https://doi.org/10.1186/s13148-019-0618-0
Ishiguro A, Yagi S, Uyama Y (2013) Characteristics of pharmacogenomics/biomarker-guided clinical trials for regulatory approval of anti-cancer drugs in Japan. J Hum Genet 58(6):313–316. https://doi.org/10.1038/jhg.2013.36
Izzo JG, Wu X, Wu TT, Huang P, Lee JS, Liao Z et al (2009) Therapy-induced expression of NF-kappaB portends poor prognosis in patients with localized esophageal cancer undergoing preoperative chemoradiation. Dis Esophagus 22(2):127–132. https://doi.org/10.1111/j.1442-2050.2008.00884.x
Jacobs I, Gentry-Maharaj A, Burnell M, Manchanda R, Singh N, Sharma A, Ryan A, Seif MW, Amso NN, Turner G, Brunell C, Fletcher G, Rangar R, Ford K, Godfrey K, Lopes A, Oram D, Herod J, Williamson K et al (2011) Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women: a case-control study within the UKCTOCS cohort. Lancet Oncol 12(1):38–48. https://doi.org/10.1016/s1470-2045(10)70268-0
Jácome AA, Sankarankutty AK, dos Santos JS (2015) Adjuvant therapy for gastric cancer: what have we learned since INT0116? World J Gastroenterol 21(13):3850–3859. https://doi.org/10.3748/wjg.v21.i13.3850
Jafri MA, Ansari SA, Alqahtani MH, Shay JW (2016) Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies. Genome Med 8(1):69–69. https://doi.org/10.1186/s13073-016-0324-x
Jafrin S, Aziz MA, Anonna SN, Akter T, Naznin NE, Reza S, Islam MS (2020) Association of TP53 codon 72 Arg>Pro polymorphism with breast and lung cancer risk in the south Asian population: a meta-analysis. Asian Pac J Cancer Prev 21(6):1511–1519. http://europepmc.org/abstract/MED/32592343. https://doi.org/10.31557/APJCP.2020.21.6.1511
Jemal A, Center MM, DeSantis C, Ward EM (2010) Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 19(8):1893–1907. https://doi.org/10.1158/1055-9965.EPI-10-0437
Jensen EV, Jordan VC (2003) The estrogen receptor: a model for molecular medicine. Clin Cancer Res 9(6):1980–1989
Jézéquel P, Campion L, Spyratos F, Loussouarn D, Campone M, Guérin-Charbonnel C, Joalland MP, André J, Descotes F, Grenot C, Roy P, Carlioz A, Martin PM, Chassevent A, Jourdan ML, Ricolleau G (2012) Validation of tumor-associated macrophage ferritin light chain as a prognostic biomarker in node-negative breast cancer tumors: a multicentric 2004 national PHRC study. Int J Cancer 131(2):426–437. https://doi.org/10.1002/ijc.26397
Jiang T, Gao G, Fan G, Li M, Zhou C (2015) FGFR1 amplification in lung squamous cell carcinoma: a systematic review with meta-analysis. Lung Cancer (Amsterdam, Netherlands) 87(1):1–7. https://doi.org/10.1016/j.lungcan.2014.11.009
Jiao R, Luo H, Xu W, Ge H (2019) Immune checkpoint inhibitors in esophageal squamous cell carcinoma: progress and opportunities. Onco Targets Ther 12:6023–6032. . http://europepmc.org/abstract/MED/31551657. https://doi.org/10.2147/OTT.S214579
Jiménez P, Chueca E, Arruebo M, Strunk M, Solanas E, Serrano T et al (2017) CD24 expression is increased in 5-fluorouracil-treated esophageal adenocarcinoma cells. Front Pharmacol 8:321. https://doi.org/10.3389/fphar.2017.00321
Jinjia C, Xiaoyu W, Hui S, Wenhua L, Zhe Z, Xiaodong Z, Midie X (2019) The use of DNA repair genes as prognostic indicators of gastric cancer. J Cancer 10(20):4866–4875. https://doi.org/10.7150/jca.31062
Johansson HJ, Sanchez BC, Mundt F, Forshed J, Kovacs A, Panizza E et al (2013) Retinoic acid receptor alpha is associated with tamoxifen resistance in breast cancer. Nat Commun 4(1):1–10
Jones P. A. (1996). DNA methylation errors and cancer. Cancer Res, 56(11), 2463–2467
Jones K, Vari F, Keane C et al (2013) Serum CD163 and TARC as disease response biomarkers in classical Hodgkin lymphoma. Clin Cancer Res 19(731–742):93
Jones K, Nourse JP, Keane C et al (2014) Plasma microRNA are disease response biomarkers in classical Hodgkin lymphoma. Clin Cancer Res 20(253–264):94
Kanagavel D, Fedyanin M, Tryakin A, Tjulandin S (2015) Second-line treatment of metastatic gastric cancer: current options and future directions. World J Gastroenterol 21(41):11621–11635. https://doi.org/10.3748/wjg.v21.i41.11621
Kang SM, Sung HJ, Ahn JM, Park JY, Lee SY, Park CS, Cho JY (2011) The haptoglobin β chain as a supportive biomarker for human lung cancers. Mol BioSyst 7(4):1167–1175. https://doi.org/10.1039/c0mb00242a
Kang K, Huang YH, Li HP, Guo SM (2018) Expression of UCA1 and MALAT1 long-chain non-coding RNAs in esophageal squamous cell carcinoma tissues is predictive of patient prognosis. Arch Med Sci 14(4):752–759. https://doi.org/10.5114/aoms.2018.73713
Katz SJ, Morrow M (2013) Addressing overtreatment in breast cancer: the doctors’ dilemma. Cancer 119(20):3584–3588. https://doi.org/10.1002/cncr.28260
Kerr KM, Bubendorf L, Edelman MJ, Marchetti A, Mok T, Novello S, O’Byrne K, Stahel R, Peters S, Felip E, Panel Members (2014) Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. Ann Oncol 25(9):1681–1690. https://doi.org/10.1093/annonc/mdu145
Khomiak A, Brunner M, Kordes M, Lindblad S, Miksch RC, Öhlund D, Regel I (2020) Recent discoveries of diagnostic, prognostic and predictive biomarkers for pancreatic cancer. Cancer 12(11):3234. https://doi.org/10.3390/cancers12113234
Khorasani ABS, Pourbagheri-Sigaroodi A, Pirsalehi A, Safaroghli-Azar A, Zali MR, Bashash D (2021) The PI3K/Akt/mTOR signaling pathway in gastric cancer; from oncogenic variations to the possibilities for pharmacologic interventions. Eur J Pharmacol 898:173983. https://doi.org/10.1016/j.ejphar.2021.173983
Kigasawa H, Fujiwara M, Ishii J, Chiba T, Terado Y, Shimoyamada H et al (2017) Altered expression of cytokeratin 7 and CD117 in transitional mucosa adjacent to human colorectal cancer. Oncol Lett 14(1):119–126. https://doi.org/10.3892/ol.2017.6156
Kim J, Kim E, Lee M (2018) Exosomes as diagnostic biomarkers in cancer. Mol Cell Toxicol 14(2):113–122. https://doi.org/10.1007/s13273-018-0014-4
Klein AP (2019) Pancreatic cancer: a growing burden. Lancet Gastroenterol Hepatol 4(12):895–896. https://doi.org/10.1016/S2468-1253(19)30323-1
Knowles PP, Murray-Rust J, Kjaer S, Scott RP, Hanrahan S, Santoro M, Ibáñez CF, McDonald NQ (2006) Structure and chemical inhibition of the RET tyrosine kinase domain. J Biol Chem 281(44):33577–33587. https://doi.org/10.1074/jbc.M605604200
Kohli M, Ho Y, Hillman D, Van Etten J, Henzler C, Yang R et al (2017) Androgen receptor variant AR-V9 is coexpressed with AR-V7 in prostate cancer metastases and predicts abiraterone resistance. Clin Cancer Res 23(16):4704–4715. https://doi.org/10.1158/1078-0432.ccr-17-0017
Kuroki M, Matsuo Y, Kinugasa T, Matsuoka Y (1992) Three different NCA species, CGM6/CD67, NCA-95, and NCA-90, are comprised in the major 90 to 100-kDa band of granulocyte NCA detectable upon SDS-polyacrylamide gel electrophoresis. Biochem Biophys Res Commun 182(2):501–506. https://doi.org/10.1016/0006-291x(92)91760-n
Kurtz DM, Green MR, Bratman SV et al (2015) Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. Blood 125(3679–3687):104
Kutryb-Zajac B, Koszalka P, Mierzejewska P, Bulinska A, Zabielska MA, Brodzik K et al (2018) Adenosine deaminase inhibition suppresses progression of 4T1 murine breast cancer by adenosine receptor-dependent mechanisms. J Cell Mol Med 22(12):5939–5954. https://doi.org/10.1111/jcmm.13864
Laird PW (2003) The power and the promise of DNA methylation markers. Nat Rev Cancer 3(4):253–266. https://doi.org/10.1038/nrc1045
Langer R, Specht K, Becker K, Ewald P, Bekesch M, Sarbia M et al (2005) Association of pretherapeutic expression of chemotherapy-related genes with response to neoadjuvant chemotherapy in Barrett carcinoma. Clin Cancer Res 11(20):7462. https://doi.org/10.1158/1078-0432.CCR-05-0042
Langer R, Ott K, Feith M, Lordick F, Specht K, Becker K, Hofler H (2010) High pretherapeutic thymidylate synthetase and MRP-1 protein levels are associated with nonresponse to neoadjuvant chemotherapy in oesophageal adenocarcinoma patients. J Surg Oncol 102(5):503–508. https://doi.org/10.1002/jso.21641
Lavery A, Turkington RC (2021) Transcriptomic biomarkers for predicting response to neoadjuvant treatment in oesophageal cancer. Gastroenterol Rep 8(6):411–424. https://doi.org/10.1093/gastro/goaa065
Lazzeri M, Haese A, Abrate A, de la Taille A, Redorta JP, McNicholas T, Lughezzani G, Lista G, Larcher A, Bini V, Cestari A, Buffi N, Graefen M, Bosset O, Le Corvoisier P, Breda A, de la Torre P, Fowler L, Roux J, Guazzoni G (2013) Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project. BJU Int 112(3):313–321. https://doi.org/10.1111/bju.12217
Leary RJ, Sausen M, Kinde I, Papadopoulos N, Carpten JD, Craig D et al (2012) Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci Transl Med 4(162):162ra154. https://doi.org/10.1126/scitranslmed.3004742
Lee N, Poon R, Shek F, Ng I, Luk J (2010) Role of cadherin-17 in oncogenesis and potential therapeutic implications in hepatocellular carcinoma. Biochim Biophys Acta 1806:138–145. https://doi.org/10.1016/j.bbcan.2010.05.002
Lehtiö J, De Petris L (2010) Lung cancer proteomics, clinical and technological considerations. J Proteomics 73(10):1851–1863. https://doi.org/10.1016/j.jprot.2010.05.015
Lennerz JK, Kwak EL, Ackerman A, Michael M, Fox SB, Bergethon K et al (2011) MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol 29(36):4803–4810. https://doi.org/10.1200/jco.2011.35.4928
Li Destri G, Rubino AS, Latino R, Giannone F, Lanteri R, Scilletta B, Di Cataldo A (2015) Preoperative carcinoembryonic antigen and prognosis of colorectal cancer. An independent prognostic factor still reliable. Int Surg 100(4):617–625. https://doi.org/10.9738/INTSURG-D-14-00100.1
Li F, Sethi G (2010) Targeting transcription factor NF-kappaB to overcome chemoresistance and radioresistance in cancer therapy. Biochim Biophys Acta 1805(2):167–180. https://doi.org/10.1016/j.bbcan.2010.01.002
Li MX, Liu XM, Zhang XF, Zhang JF, Wang WL, Zhu Y et al (2014a) Prognostic role of neutrophil-to-lymphocyte ratio in colorectal cancer: a systematic review and meta-analysis. Int J Cancer 134(10):2403–2413. https://doi.org/10.1002/ijc.28536
Li QT, Kang W, Wang M, Yang J, Zuo Y, Zhang W, Su DK (2014b) Association between esophageal cancer risk and EPHX1 polymorphisms: a meta-analysis. World J Gastroenterol 20(17):5124–5130. https://doi.org/10.3748/wjg.v20.i17.5124
Li W, Li C, Zhou T, Liu X, Liu X, Li X, Chen D (2017) Role of exosomal proteins in cancer diagnosis. Mol Cancer 16(1):145. https://doi.org/10.1186/s12943-017-0706-8
Lipson D, Capelletti M, Yelensky R, Otto G, Parker A, Jarosz M, Curran JA, Balasubramanian S, Bloom T, Brennan KW, Donahue A, Downing SR, Frampton GM, Garcia L, Juhn F, Mitchell KC, White E, White J, Zwirko Z, Peretz T et al (2012) Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med 18(3):382–384. https://doi.org/10.1038/nm.2673
Litwin MS, Tan HJ (2017) The diagnosis and treatment of prostate cancer: a review. JAMA 317(24):2532–2542. https://doi.org/10.1001/jama.2017.7248
Liu D (2019) Cancer biomarkers for targeted therapy. Biomarkers Res 7:25. https://doi.org/10.1186/s40364-019-0178-7
Liu T, Zhang X, Gao S, Jing F, Yang Y, Du L et al (2016a) Exosomal long noncoding RNA CRNDE-h as a novel serum-based biomarker for diagnosis and prognosis of colorectal cancer. Oncotarget 7(51):85551–85563. https://doi.org/10.18632/oncotarget.13465
Liu Z, Yang T, Xu Z, Cao X (2016b) Upregulation of the long non-coding RNA BANCR correlates with tumor progression and poor prognosis in esophageal squamous cell carcinoma. Biomed Pharmacother 82:406–412. https://doi.org/10.1016/j.biopha.2016.05.014
Liu MX, Liao J, Xie M, Gao ZK, Wang XH, Zhang Y et al (2018) miR-93-5p transferred by exosomes promotes the proliferation of esophageal cancer cells via intercellular communication by targeting PTEN. Biomed Environ Sci 31(3):171–185. https://doi.org/10.3967/bes2018.023
Loktionov A (2020) Biomarkers for detecting colorectal cancer non-invasively: DNA, RNA or proteins? World J Gastrointest Oncol 12(2):124–148. https://doi.org/10.4251/wjgo.v12.i2.124
Longo V, Brunetti O, Gnoni A, Cascinu S, Gasparini G, Lorusso V et al (2016) Angiogenesis in pancreatic ductal adenocarcinoma: a controversial issue. Oncotarget 7(36):58649–58658
Lowe KA, Shah C, Wallace E, Anderson G, Paley P, McIntosh M, Andersen MR, Scholler N, Bergan L, Thorpe J, Urban N, Drescher CW (2008) Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high-risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev 17(9):2480–2487. https://doi.org/10.1158/1055-9965.EPI-08-0150
Lu R, Sun X, Xiao R, Zhou L, Gao X, Guo L (2012) Human epididymis protein 4 (HE4) plays a key role in ovarian cancer cell adhesion and motility. Biochem Biophys Res Commun 419(2):274–280. https://doi.org/10.1016/j.bbrc.2012.02.008
Ma G, Wang Q, Lv C, Qiang F, Hua Q, Chu H et al (2015) The prognostic significance of HOTAIR for predicting clinical outcome in patients with digestive system tumors. J Cancer Res Clin Oncol 141(12):2139–2145. https://doi.org/10.1007/s00432-015-1980-8
Macerelli M, Caramella C, Faivre L, Besse B, Planchard D, Polo V, Ngo Camus M, Celebic A, Koubi-Pick V, Lacroix L, Pignon JP, Soria JC (2014) Does KRAS mutational status predict chemoresistance in advanced non-small cell lung cancer (NSCLC)? Lung Cancer (Amsterdam, Netherlands) 83(3):383–388. https://doi.org/10.1016/j.lungcan.2013.12.013
Maciel CM, Junqueira M, Paschoal ME, Kawamura MT, Duarte RL, Carvalho Mda G, Domont GB (2005) Differential proteomic serum pattern of low molecular weight proteins expressed by adenocarcinoma lung cancer patients. J Exp Ther Oncol 5(1):31–38. PMID: 16416599
Magnusson K, de Wit M, Brennan DJ, Johnson LB, McGee SF, Lundberg E et al (2011) SATB2 in combination with cytokeratin 20 identifies over 95% of all colorectal carcinomas. Am J Surg Pathol 35(7):937–948. https://doi.org/10.1097/PAS.0b013e31821c3dae
Massova I, Kotra LP, Fridman R, Mobashery S (1998) Matrix metalloproteinases: structures, evolution, and diversification. FASEB J 12(12):1075–1095
Matsumoto Y, Kano M, Akutsu Y, Hanari N, Hoshino I, Murakami K et al (2016) Quantification of plasma exosome is a potential prognostic marker for esophageal squamous cell carcinoma. Oncol Rep 36(5):2535–2543. https://doi.org/10.3892/or.2016.5066
Mayerle J, Kalthoff H, Reszka R, Kamlage B, Peter E, Schniewind B et al (2018) Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis. Gut 67(1):128–137. https://doi.org/10.1136/gutjnl-2016-312,432
Mazières J, Peters S, Lepage B, Cortot AB, Barlesi F, Beau-Faller M, Besse B, Blons H, Mansuet-Lupo A, Urban T, Moro-Sibilot D, Dansin E, Chouaid C, Wislez M, Diebold J, Felip E, Rouquette I, Milia JD, Gautschi O (2013) Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol 31(16):1997–2003. https://doi.org/10.1200/JCO.2012.45.6095
McBride OW, Swan DC, Tronick SR, Gol R, Klimanis D, Moore DE, Aaronson SA (1983) Regional chromosomal localization of N-ras, K-ras-1, K-ras-2 and myb oncogenes in human cells. Nucleic Acids Res 11(23):8221–8236. https://doi.org/10.1093/nar/11.23.8221
McGregor MJ, Fadhil W, Wharton R, Yanagisawa Y, Presz M, Pritchard A et al (2015) Aberrant P53 expression lacks prognostic or predictive significance in colorectal cancer: results from the VICTOR trial. Anticancer Res 35(3):1641
McGuire WL (1975) Current status of estrogen receptors in human breast cancer. Cancer 36(2):638–644
McIntosh MW, Drescher C, Karlan B, Scholler N, Urban N, Hellstrom KE, Hellstrom I (2004) Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. Gynecol Oncol 95(1):9–15. https://doi.org/10.1016/j.ygyno.2004.07.039
Meehan J, Gray M, Martínez-Pérez C, Kay C, Pang LY, Fraser JA, Poole AV, Kunkler IH, Langdon SP, Argyle D, Turnbull AK (2020) Precision medicine and the role of biomarkers of radiotherapy response in breast cancer. Front Oncol 10:628. https://doi.org/10.3389/fonc.2020.00628
Ménétrier-Caux C, Ray-Coquard I, Blay J-Y, Caux C (2019) Lymphopenia in cancer patients and its effects on response to immunotherapy: an opportunity for combination with cytokines? J Immunother Cancer 7(1):85. https://doi.org/10.1186/s40425-019-0549-5
Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, Lewis S, Davies S, Philpott S, Lopes A, Godfrey K, Oram D, Herod J, Williamson K, Seif MW, Scott I, Mould T, Woolas R, Murdoch J et al (2009a) Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol 10(4):327–340. https://doi.org/10.1016/s1470-2045(09)70026-9
Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, Lewis S, Davies S, Philpott S, Lopes A, Godfrey K, Oram D, Herod J, Williamson K, Seif MW, Scott I, Mould T, Woolas R, Murdoch J, Dobbs S et al (2009b) Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol 10(4):327–340. https://doi.org/10.1016/S1470-2045(09)70026-9
Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science (New York, NY) 266(5182):66–71. https://doi.org/10.1126/science.7545954
Milner BJ, Allan LA, Eccles DM, Kitchener HC, Leonard RC, Kelly KF, Parkin DE, Haites NE (1993) p53 mutation is a common genetic event in ovarian carcinoma. Cancer Res 53(9):2128–2132
Mitchell K, Williams H (2019) Emerging genomic biomarkers for improving kidney, prostate, and bladder cancer health disparities outcomes. Urol Oncol. https://doi.org/10.1016/j.urolonc.2019.04.024
Miyazaki I, Kawai T, Harada Y, Moriyasu F (2010) A predictive factor for the response to S-1 plus cisplatin in gastric cancer. World J Gastroenterol 16(36):4575–4582. https://doi.org/10.3748/wjg.v16.i36.4575
Moh M, Krings G, Ates D, Aysal A, Kim GE, Rabban JT (2016) SATB2 expression distinguishes ovarian metastases of colorectal and appendiceal origin from primary ovarian tumors of mucinous or endometrioid type. Am J Surg Pathol 40(3):419–432. https://doi.org/10.1097/pas.0000000000000553
Mohammadi N, Alimohammadian M, Feizesani A, Poustchi H, Alizadeh A, Yaseri M et al (2021) The marginal causal effect of opium consumption on the upper gastrointestinal cancer death using parametric g-formula: an analysis of 49,946 cases in the Golestan cohort study, Iran. PLoS One 16:e0246004. https://doi.org/10.1371/journal.pone.0246004
Mok TS (2011) Personalized medicine in lung cancer: what we need to know. Nat Rev Clin Oncol 8(11):661–668. https://doi.org/10.1038/nrclinonc.2011.126
Molina R, Barak V, van Dalen A, Duffy MJ, Einarsson R, Gion M, Goike H, Lamerz R, Nap M, Sölétormos G, Stieber P (2005) Tumor markers in breast cancer—European Group on Tumor Markers recommendations. Tumour Biol 26(6):281–293. https://doi.org/10.1159/000089260
Montagnana M, Danese E, Giudici S, Franchi M, Guidi GC, Plebani M, Lippi G (2011) HE4 in ovarian cancer: from discovery to clinical application. Adv Clin Chem 55:1–20
Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, Steinhoff M, Messerlian G, DiSilvestro P, Granai CO, Bast RC Jr (2008) The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 108(2):402–408. https://doi.org/10.1016/j.ygyno.2007.10.017
Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, Gajewski W, Kurman R, Bast RC Jr, Skates SJ (2009) A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 112(1):40–46. https://doi.org/10.1016/j.ygyno.2008.08.031
Moore RG, Miller MC, Eklund EE, Lu KH, Bast RC Jr, Lambert-Messerlian G (2012) Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age. Am J Obstet Gynecol 206(4):349.e1–349.e3497. https://doi.org/10.1016/j.ajog.2011.12.028
Moore HB, Culp-Hill R, Reisz JA, Lawson PJ, Sauaia A, Schulick RD et al (2019) The metabolic time line of pancreatic cancer: opportunities to improve early detection of adenocarcinoma. Am J Surg 218(6):1206–1212. https://doi.org/10.1016/j.amjsurg.2019.08.015
Moreno-Aspitia A, Hillman DW, Dyar SH, Tenner KS, Gralow J, Kaufman PA, Davidson NE, Lafky JM, Reinholz MM, Lingle WL, Kutteh LA, Carney WP, Dueck AC, Perez EA (2013) Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: results from North Central Cancer Treatment Group adjuvant trial N9831. Cancer 119(15):2675–2682. https://doi.org/10.1002/cncr.28130
Munteanu VC, Munteanu RA, Onaciu A, Berindan-Neagoe I, Petrut B, Coman I (2020) MiRNA-based inspired approach in diagnosis of prostate cancer. Medicina (Kaunas) 56(2):94. https://doi.org/10.3390/medicina56020094
Murer P, Plüss L, Neri D (2020) A novel human monoclonal antibody specific to the A33 glycoprotein recognizes colorectal cancer and inhibits metastasis. mAbs 12(1):1714371. https://doi.org/10.1080/19420862.2020.1714371
Nadji M, Gomez-Fernandez C, Ganjei-Azar P, Morales AR (2005) Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers. Am J Clin Pathol 123(1):21–27. https://doi.org/10.1309/4wv79n2ghj3x1841
Nakae M, Iwamoto I, Fujino T, Maehata Y, Togami S, Yoshinaga M, Douchi T (2006) Preoperative plasma osteopontin level as a biomarker complementary to carbohydrate antigen 125 in predicting ovarian cancer. J Obstet Gynaecol Res 32(3):309–314. https://doi.org/10.1111/j.1447-0756.2006.00403.x
Naoi Y, Noguchi S (2016) Multi-gene classifiers for prediction of recurrence in breast cancer patients. Breast Cancer (Tokyo, Japan) 23(1):12–18. https://doi.org/10.1007/s12282-015-0596-9
Niedergethmann M, Hildenbrand R, Wolf G, Verbeke CS, Richter A, Post S (2000) Angiogenesis and cathepsin expression are prognostic factors in pancreatic adenocarcinoma after curative resection. Int J Pancreatol 28(1):31–39. https://doi.org/10.1385/ijgc:28:1:31
Niederreither K, Dollé P (2008) Retinoic acid in development: towards an integrated view. Nat Rev Genet 9(7):541–553. https://doi.org/10.1038/nrg2340
Niyaz M, Ainiwaer J, Abudureheman A, Zhang L, Sheyhidin I, Turhong A et al (2020) Association between TP53 gene deletion and protein expression in esophageal squamous cell carcinoma and its prognostic significance. Oncol Lett 20(2):1855–1865. https://doi.org/10.3892/ol.2020.11709
Nodin B, Zendehrokh N, Sundström M, Jirström K (2013) Clinicopathological correlates and prognostic significance of KRAS mutation status in a pooled prospective cohort of epithelial ovarian cancer. Diagn Pathol 8:106. https://doi.org/10.1186/1746-1596-8-106
Nordlinger B, Guiguet M, Vaillant JC, Balladur P, Boudjema K, Bachellier P, Jaeck D (1996) Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Française de Chirurgie. Cancer 77(7):1254–1262
O’Reilly D (2019) Defining end points in phase II trials of metastatic castration-resistant prostate cancer. Re: impact of addition of metformin to abiraterone in metastatic castration-resistant prostate cancer patients with disease progressing while receiving abiraterone treatment (MetAb-Pro): phase 2 pilot study. Clin Genitourin Cancer 17(5):e886–e887. https://doi.org/10.1016/j.clgc.2019.07.010
Oh HH, Joo YE (2020) Novel biomarkers for the diagnosis and prognosis of colorectal cancer. Intest Res 18(2):168–183. https://doi.org/10.5217/ir.2019.00080
Oh JJ, Grosshans DR, Wong SG, Slamon DJ (1999) Identification of differentially expressed genes associated with HER-2/neu overexpression in human breast cancer cells. Nucleic Acids Res 27(20):4008–4017. https://doi.org/10.1093/nar/27.20.4008
Oki Y, Neelapu SS, Fanale M et al (2015) Detection of classical Hodgkin lymphoma specific sequence in peripheral blood using a next-generation sequencing approach. Br J Haematol 169:689–693
Olayide A, Samuel O, Ganiyu R, Moses A, Gafar O, Abiola D, Dapo K, John A (2015) How effective is the treatment of locally advanced and metastatic breast cancer in developing centres?: A retrospective review. Ethiop J Health Sci 25(4):337–344. https://doi.org/10.4314/ejhs.v25i4.7
Opstelten R, de Kivit S, Slot MC, van den Biggelaar M, Iwaszkiewicz-Grześ D, Gliwiński M et al (2020) GPA33: a marker to identify stable human regulatory T cells. J Immunol 204(12):3139–3148. https://doi.org/10.4049/jimmunol.1901250
Pang WW, Abdul-Rahman PS, Wan-Ibrahim WI, Hashim OH (2010) Can the acute-phase reactant proteins be used as cancer biomarkers? Int J Biol Markers 25(1):1–11
Pang H, Lu H, Song H, Meng Q, Zhao Y, Liu N, Lan F, Liu Y, Yan S, Dong X, Cai L (2013) Prognostic values of osteopontin-c, E-cadherin and β-catenin in breast cancer. Cancer Epidemiol 37(6):985–992. https://doi.org/10.1016/j.canep.2013.08.005
Park JB, Rhim JS, Park SC, Kimm SW, Kraus MH (1989) Amplification, overexpression, and rearrangement of the erbB-2 protooncogene in primary human stomach carcinomas. Cancer Res 49(23):6605–6609
Park YJ, Park KJ, Park JG, Lee KU, Choe KJ, Kim JP (1999) Prognostic factors in 2230 Korean colorectal cancer patients: analysis of consecutively operated cases. World J Surg 23(7):721–726. https://doi.org/10.1007/pl00012376
Pashaei E, Pashaei E, Ahmady M, Ozen M, Aydin N (2017) Meta-analysis of miRNA expression profiles for prostate cancer recurrence following radical prostatectomy. PLoS One 12:e0179543. https://doi.org/10.1371/journal.pone.0179543
Passiglia F, Caparica R, Giovannetti E, Giallombardo M, Listi A, Diana P, Cirrincione G, Caglevic C, Raez LE, Russo A, Rolfo C (2016) The potential of neurotrophic tyrosine kinase (NTRK) inhibitors for treating lung cancer. Expert Opin Investig Drugs 25(4):385–392. https://doi.org/10.1517/13543784.2016.1152261
Paulson TG, Maley CC, Li X, Li H, Sanchez CA, Chao DL et al (2009) Chromosomal instability and copy number alterations in Barrett’s esophagus and esophageal adenocarcinoma. Clin Cancer Res 15(10):3305–3314. https://doi.org/10.1158/1078-0432.ccr-08-2494
Peng W, Wang Z, Fan H (2017) LncRNA NEAT1 impacts cell proliferation and apoptosis of colorectal cancer via regulation of Akt signaling. Pathol Oncol Res 23(3):651–656. https://doi.org/10.1007/s12253-016-0172-4
Pereira-Fantini PM, Judd LM, Kalantzis A, Peterson A, Ernst M, Heath JK, Giraud AS (2010) A33 antigen-deficient mice have defective colonic mucosal repair. Inflamm Bowel Dis 16(4):604–612. https://doi.org/10.1002/ibd.21114
Phillips BE, Tubbs RR, Rice TW, Rybicki LA, Plesec T, Rodriguez CP et al (2013) Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagus and gastro-esophageal junction. Dis Esophagus 26(3):299–304. https://doi.org/10.1111/j.1442-2050.2012.01369.x
Phua LC, Goh S, Tai DWM, Leow WQ, Alkaff SMF, Chan CY et al (2018) Metabolomic prediction of treatment outcome in pancreatic ductal adenocarcinoma patients receiving gemcitabine. Cancer Chemother Pharmacol 81(2):277–289. https://doi.org/10.1007/s00280-017-3475-6
Pistol-Tanase C, Raducan E, Dima SO, Albulescu L, Alina I, Marius P et al (2008) Assessment of soluble angiogenic markers in pancreatic cancer. Biomark Med 2(5):447–455. https://doi.org/10.2217/17520363.2.5.447
Plattel WJ, Alsada ZN, van Imhoff GW et al (2016) Biomarkers for evaluation of treatment response in classical Hodgkin lymphoma: comparison of sGalectin-1, sCD163 and sCD30 with TARC. Br J Haematol 175:868–875
Polley MY, Freidlin B, Korn EL, Conley BA, Abrams JS, McShane LM (2013) Statistical and practical considerations for clinical evaluation of predictive biomarkers. J Natl Cancer Inst 105(22):1677–1683. https://doi.org/10.1093/jnci/djt282
Poola I, Shokrani B, Bhatnagar R, DeWitty RL, Yue Q, Bonney G (2006) Expression of carcinoembryonic antigen cell adhesion molecule 6 oncoprotein in atypical ductal hyperplastic tissues is associated with the development of invasive breast cancer. Clin Cancer Res 12(15):4773–4783. https://doi.org/10.1158/1078-0432.CCR-05-2286
Popescu NC, King CR, Kraus MH (1989) Localization of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12-21.32. Genomics 4(3):362–366. https://doi.org/10.1016/0888-7543(89)90343-1
Pradhan S, Sperduto JL, Farino CJ, Slater JH (2018) Engineered in vitro models of tumor dormancy and reactivation. J Biol Eng 12:37. https://doi.org/10.1186/s13036-018-0120-9
Press MF, Pike MC, Hung G, Zhou JY, Ma Y, George J, Dietz-Band J, James W, Slamon DJ, Batsakis JG et al (1994) Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis. Cancer Res 54(21):5675–5682. PMID: 7522962
Prica F, Radon T, Cheng Y, Crnogorac-Jurcevic T (2016) The life and works of S100P—from conception to cancer. Am J Cancer Res 6(2):562–576
Qian C, Xia Y, Ren Y, Yin Y, Deng A (2017) Identification and validation of PSAT1 as a potential prognostic factor for predicting clinical outcomes in patients with colorectal carcinoma. Oncol Lett 14(6):8014–8020. https://doi.org/10.3892/ol.2017.7211
Ravdin PM, Green S, Dorr TM, McGuire WL, Fabian C, Pugh RP, Carter RD, Rivkin SE, Borst JR, Belt RJ (1992) Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J Clin Oncol 10(8):1284–1291. https://doi.org/10.1200/JCO.1992.10.8.1284
Rawla P, Sunkara T, Barsouk A (2019) Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Prz Gastroenterol 14(2):89–103. https://doi.org/10.5114/pg.2018.81072
Rebours V, Lévy P, Mosnier JF, Scoazec JY, Soubeyrand MS, Fléjou JF et al (2010) Pathology analysis reveals that dysplastic pancreatic ductal lesions are frequent in patients with hereditary pancreatitis. Clin Gastroenterol Hepatol 8(2):206–212. https://doi.org/10.1016/j.cgh.2009.09.009
Rein BJD, Gupta S, Dada R, Safi J, Michener C, Agarwal A (2011) Potential markers for detection and monitoring of ovarian cancer. J Oncol 2011:1–17. https://doi.org/10.1155/2011/475983
Renehan AG, Jones J, Potten C, Shalet S, O’Dwyer S (2000) Elevated serum insulin-like growth factor (IGF)-II and IGF binding protein-2 in patients with colorectal cancer. Br J Cancer 83:1344–1350. https://doi.org/10.1054/bjoc.2000.1462
Renouf DJ, Zhai R, Sun B, Xu W, Cheung WY, Heist RS et al (2013) Association of MDM2 T309G and p53 Arg72Pro polymorphisms and gastroesophageal reflux disease with survival in esophageal adenocarcinoma. J Gastroenterol Hepatol 28(9):1482–1488. https://doi.org/10.1111/jgh.12286
Riaz IB, Wang L, Kohli M (2018) Liquid biopsy approach in the management of prostate cancer. Transl Res 201:60–70
Ricciardi GR, Russo A, Franchina T, Ferraro G, Zanghì M, Picone A, Scimone A, Adamo V (2014) NSCLC and HER2: between lights and shadows. J Thoracic Oncol 9(12):1750–1762. https://doi.org/10.1097/JTO.0000000000000379
Robinson K, Creed J, Reguly B, Powell C, Wittock R, Klein D et al (2010) Accurate prediction of repeat prostate biopsy outcomes by a mitochondrial DNA deletion assay. Prostate Cancer Prostatic Dis 13(2):126–131. https://doi.org/10.1038/pcan.2009.64
Rodríguez-Piñeiro AM, Blanco-Prieto S, Sánchez-Otero N, Rodríguez-Berrocal FJ, de la Cadena MP (2010) On the identification of biomarkers for non-small cell lung cancer in serum and pleural effusion. J Proteomics 73(8):1511–1522. https://doi.org/10.1016/j.jprot.2010.03.005
Roig AI, Wright WE, Shay JW (2009) Is telomerase a novel target for metastatic colon cancer? Curr Colorectal Cancer Rep 5(4):203. https://doi.org/10.1007/s11888-009-0028-3
Roschewski M, Dunleavy K, Pittaluga S et al (2015) Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. Lancet Oncol 16:541–549
Russo A, Bazan V, Iacopetta B, Kerr D, Soussi T, Gebbia N (2005) The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J Clin Oncol 23(30):7518–7528. https://doi.org/10.1200/JCO.2005.00.471
Saffari B, Jones LA, el-Naggar A, Felix JC, George J, Press MF (1995) Amplification and overexpression of HER-2/neu (c-erbB2) in endometrial cancers: correlation with overall survival. Cancer Res 55(23):5693–5698
Sahni S, Nahm C, Krisp C, Molloy MP, Mehta S, Maloney S et al (2020) Identification of novel biomarkers in pancreatic tumor tissue to predict response to neoadjuvant chemotherapy. Front Oncol 10:237. https://doi.org/10.3389/fonc.2020.00237
Salehi M, Sharifi M (2018) Exosomal miRNAs as novel cancer biomarkers: challenges and opportunities. J Cell Physiol 233(9):6370–6380. https://doi.org/10.1002/jcp.26481
Salto-Tellez M, Tan S-Y, Chiu L-L, Koay ES-C (2005) Dinucleotide microsatellite repeats are essential for the diagnosis of microsatellite instability in colorectal cancer in Asian patients. World J Gastroenterol 11(18):2781–2783. https://doi.org/10.3748/wjg.v11.i18.2781
Samuels Y, Velculescu VE (2004) Oncogenic mutations of PIK3CA in human cancers. Cell Cycle 3(10):1221–1224. https://doi.org/10.4161/cc.3.10.1164
Sanda MG, Feng Z, Howard DH, Tomlins SA, Sokoll LJ, Chan DW et al (2017) Association between combined TMPRSS2:ERG and PCA3 RNA urinary testing and detection of aggressive prostate cancer. JAMA Oncol 3(8):1085–1093
Sanhueza C, Kohli M (2018) Clinical and novel biomarkers in the management of prostate cancer. Curr Treat Options Oncol 19(2):8. https://doi.org/10.1007/s11864-018-0527-z
Sapkota M, Knoell DL (2018) Essential role of zinc and zinc transporters in myeloid cell function and host defense against infection. J Immunol Res 2018:4315140. https://doi.org/10.1155/2018/4315140
Sardesai S, Sukumar J, Kassem M, Palettas M, Stephens J, Morgan E et al (2020) Clinical impact of interruption in adjuvant Trastuzumab therapy in patients with operable HER-2 positive breast cancer. Cardiooncology 6(1):26. https://doi.org/10.1186/s40959-020-00081-9
Sawaki A, Yamada Y, Yamaguchi K, Nishina T, Doi T, Satoh T et al (2018) Regional differences in advanced gastric cancer: exploratory analyses of the AVAGAST placebo arm. Gastric Cancer 21(3):429–438. https://doi.org/10.1007/s10120-017-0773-y
Schneider MU, Rösch W, Domschke S, Domschke W (1984) Pancreatic juice protein associated with chronic pancreatitis and adenocarcinoma of the pancreas. Scand J Gastroenterol 19(2):139–144. https://doi.org/10.1080/00365521.1984.12005699
Schorge JO, Modesitt SC, Coleman RL, Cohn DE, Kauff ND, Duska LR, Herzog TJ (2010) SGO white paper on ovarian cancer: etiology, screening and surveillance. Gynecol Oncol 119(1):7–17. https://doi.org/10.1016/j.ygyno.2010.06.003
Schrohl AS, Meijer-van Gelder ME, Holten-Andersen MN, Christensen IJ, Look MP, Mouridsen HT, Brünner N, Foekens JA (2006) Primary tumor levels of tissue inhibitor of metalloproteinases-1 are predictive of resistance to chemotherapy in patients with metastatic breast cancer. Clin Cancer Res 12(23):7054–7058. https://doi.org/10.1158/1078-0432.CCR-06-0950
Senger DR, Wirth DF, Hynes RO (1979) Transformed mammalian cells secrete specific proteins and phosphoproteins. Cell 16(4):885–893. https://doi.org/10.1016/0092-8674(79)90103-x
Sepulveda AR, Hamilton SR, Allegra CJ, Grody W, Cushman-Vokoun AM, Funkhouser WK et al (2017) Molecular biomarkers for the evaluation of colorectal cancer: guideline from the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology. J Clin Oncol 35(13):1453–1486. https://doi.org/10.1200/jco.2016.71.9807
Shah MA, Ramanathan RK, Ilson DH, Levnor A, D’Adamo D, O’Reilly E et al (2006) Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastro-esophageal junction adenocarcinoma. J Clin Oncol 24(33):5201–5206. https://doi.org/10.1200/jco.2006.08.0887
Shah MA, Wainberg ZA, Catenacci DVT, Hochster HS, Ford J, Kunz P et al (2013) Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer. PLoS One 8(3):e54014. https://doi.org/10.1371/journal.pone.0054014
Sharma SV, Bell DW, Settleman J, Haber DA (2007) Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7(3):169–181. https://doi.org/10.1038/nrc2088
Shay JW, Bacchetti S (1997) A survey of telomerase activity in human cancer. Eur J Cancer 33(5):787–791. https://doi.org/10.1016/s0959-8049(97)00062-2
Shen F-F, Zhou F-Y, Xue Q-S, Pan Y, Zheng L, Zhang H et al (2013) Association between CYP1A1 polymorphisms and esophageal cancer: a meta-analysis. Mol Biol Rep 40(10):6035–6042. https://doi.org/10.1007/s11033-013-2713-1
Shi W-J, Gao J-B (2016) Molecular mechanisms of chemoresistance in gastric cancer. World J Gastrointest Oncol 8(9):673–681. https://doi.org/10.4251/wjgo.v8.i9.673
Shi M, Su RJ, Parmar KP, Chaudhry R, Sun K, Rao J, Chen M (2019) CD123: a novel biomarker for diagnosis and treatment of leukemia. Cardiovasc Hematol Disord Drug Targets 19(3):195–204. https://doi.org/10.2174/1871529X19666190627100613
Siwak DR, Carey M, Hennessy BT et al (2010) Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges. J Oncol 2010:568938. https://doi.org/10.1155/2010/568938
Skotland T, Ekroos K, Kauhanen D, Simolin H, Seierstad T, Berge V et al (2017) Molecular lipid species in urinary exosomes as potential prostate cancer biomarkers. Eur J Cancer 70:122–132. https://doi.org/10.1016/j.ejca.2016.10.011
Skrajnowska D, Bobrowska-Korczak B (2019) Role of zinc in immune system and anti-cancer defense mechanisms. Nutrients 11(10):2273. https://doi.org/10.3390/nu11102273
Slack-Davis JK, Atkins KA, Harrer C, Hershey ED, Conaway M (2009) Vascular cell adhesion molecule-1 is a regulator of ovarian cancer peritoneal metastasis. Cancer Res 69(4):1469–1476. https://doi.org/10.1158/0008-5472.CAN-08-2678
Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J (2011) Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365(14):1273–1283
Smid D, Kulda V, Srbecka K, Kubackova D, Dolezal J, Daum O et al (2016) Tissue microRNAs as predictive markers for gastric cancer patients undergoing palliative chemotherapy. Int J Oncol 48(6):2693–2703. https://doi.org/10.3892/ijo.2016.3484
Smith RA, Lam AK (2018) Liquid biopsy for investigation of cancer DNA in esophageal adenocarcinoma: cell-free plasma DNA and exosome-associated DNA. Methods Mol Biol 1756:187–194. https://doi.org/10.1007/978-1-4939-7734-5_17
Soehnlein O, Steffens S, Hidalgo A, Weber C (2017) Neutrophils as protagonists and targets in chronic inflammation. Nat Rev Immunol 17(4):248–261. https://doi.org/10.1038/nri.2017.10
Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Iyer S, Reisman A, Wilner KD, Tursi J, Blackhall F, PROFILE 1014 Investigators (2014) First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 371(23):2167–2177. https://doi.org/10.1056/NEJMoa1408440
Stocker G, Ott K, Henningsen N, Becker K, Hapfelmeier A, Lordick F et al (2009) CyclinD1 and interleukin-1 receptor antagonist polymorphisms are associated with prognosis in neoadjuvant-treated gastric carcinoma. Eur J Cancer 45(18):3326–3335. https://doi.org/10.1016/j.ejca.2009.09.021
Stockwell S (1983) Classics in oncology. George Thomas Beatson, M.D. (1848–1933). CA Cancer J Clin 33(2):105–121. https://doi.org/10.3322/canjclin.33.2.105
Strathdee G, Appleton K, Illand M, Millan DW, Sargent J, Paul J, Brown R (2001) Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes. Am J Pathol 158(3):1121–1127. https://doi.org/10.1016/S0002-9440(10)64059-X
Stroncek DF, Burns C, Martin BM, Rossi L, Marincola FM, Panelli MC (2005) Advancing cancer biotherapy with proteomics. J Immunother (Hagerstown, Md.: 1997) 28(3):183–192. https://doi.org/10.1097/01.cji.0000162781.78384.95
Su M-C, Yuan R-H, Lin C-Y, Jeng Y-M (2008) Cadherin-17 is a useful diagnostic marker for adenocarcinomas of the digestive system. Mod Pathol 21(11):1379–1386. https://doi.org/10.1038/modpathol.2008.107
Su F, Kozak KR, Imaizumi S, Gao F, Amneus MW, Grijalva V, Ng C, Wagner A, Hough G, Farias-Eisner G, Anantharamaiah GM, Van Lenten BJ, Navab M, Fogelman AM, Reddy ST, Farias-Eisner R (2010) Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer. Proc Natl Acad Sci U S A 107(46):19997–20002. https://doi.org/10.1073/pnas.1009010107
Sugihara H, Ishimoto T, Miyake K, Izumi D, Baba Y, Yoshida N et al (2015) Noncoding RNA expression aberration is associated with cancer progression and is a potential biomarker in esophageal squamous cell carcinoma. Int J Mol Sci 16(11):27824–27834. https://doi.org/10.3390/ijms161126060
Sugimoto M, Wong DT, Hirayama A, Soga T, Tomita M (2010) Capillary electrophoresis mass spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancer-specific profiles. Metabolomics 6(1):78–95. https://doi.org/10.1007/s11306-009-0178-y
Sun M, Abdollah F (2015) Re: AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. Eur Urol 68(1):162–163. https://doi.org/10.1016/j.eururo.2015.03.054
Sun Q, Zhang X, Liu T, Liu X, Geng J, He X, Liu Y, Pang D (2013) Increased expression of mitotic arrest deficient-like 1 (MAD1L1) is associated with poor prognosis and insensitive to Taxol treatment in breast cancer. Breast Cancer Res Treat 140(2):323–330. https://doi.org/10.1007/s10549-013-2633-8
Sung HJ, Ahn JM, Yoon YH, Rhim TY, Park CS, Park JY, Lee SY, Kim JW, Cho JY (2011) Identification and validation of SAA as a potential lung cancer biomarker and its involvement in metastatic pathogenesis of lung cancer. J Proteome Res 10(3):1383–1395. https://doi.org/10.1021/pr101154j
Szajnik M, Derbis M, Lach M, Patalas P, Michalak M, Drzewiecka H, Szpurek D, Nowakowski A, Spaczynski M, Baranowski W, Whiteside TL (2013) Exosomes in plasma of patients with ovarian carcinoma: potential biomarkers of tumor progression and response to therapy. Gynecol Obstet (Sunnyvale, Calif) Suppl 4:3. https://doi.org/10.4172/2161-0932.S4-003
Takahashi H, Kaniwa N, Saito Y, Sai K, Hamaguchi T, Shirao K et al (2013) Identification of a candidate single-nucleotide polymorphism related to chemotherapeutic response through a combination of knowledge-based algorithm and hypothesis-free genomic data. J Biosci Bioeng 116(6):768–773. https://doi.org/10.1016/j.jbiosc.2013.05.021
Tanase CP, Neagu M, Albulescu R, Hinescu ME (2010) Advances in pancreatic cancer detection. Adv Clin Chem 51:145–180. https://doi.org/10.1016/s0065-2423(10)51006-0
Tang W-W, Wu Q, Li S-Q, Tong Y-S, Liu Z-H, Yang T-X et al (2015) Implication of lncRNAs in pathogenesis of esophageal cancer. Onco Targets Ther 8:3219–3226. . http://europepmc.org/abstract/MED/26609239. https://doi.org/10.2147/ott.s87856
Taylor DD, Gercel-Taylor C (2008) MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol 110(1):13–21. https://doi.org/10.1016/j.ygyno.2008.04.033
Taylor PR, Abnet CC, Dawsey SM (2013) Squamous dysplasia—the precursor lesion for esophageal squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 22(4):540–552. https://doi.org/10.1158/1055-9965.EPI-12-1347
Tchetgen MB, Oesterling JE (1997) The effect of prostatitis, urinary retention, ejaculation, and ambulation on the serum prostate-specific antigen concentration. Urol Clin North Am 24(2):283–291. https://doi.org/10.1016/s0094-0143(05)70374-8
Tiwari AK, Roy HK, Lynch HT (2016) Lynch syndrome in the 21st century: clinical perspectives. QJM 109(3):151–158. https://doi.org/10.1093/qjmed/hcv137
Tobita K, Kijima H, Dowaki S, Oida Y, Kashiwagi H, Ishii M et al (2002) Thrombospondin-1 expression as a prognostic predictor of pancreatic ductal carcinoma. Int J Oncol 21(6):1189–1195
Travis WD, Brambilla E, Riely GJ (2013) New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. J Clin Oncol 31(8):992–1001. https://doi.org/10.1200/JCO.2012.46.9270
Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG (2015) Introduction to the 2015 World Health Organization classification of tumors of the lung, pleura, thymus, and heart. J Thorac Oncol 10(9):1240–1242. https://doi.org/10.1097/JTO.0000000000000663
Tsuchida N, Ryder T, Ohtsubo E (1982) Nucleotide sequence of the oncogene encoding the p21 transforming protein of Kirsten murine sarcoma virus. Science (New York, NY) 217(4563):937–939. https://doi.org/10.1126/science.6287573
Tumas J, Baskirova I, Petrenas T, Norkuniene J, Strupas K, Sileikis A (2019) Towards a personalized approach in pancreatic cancer diagnostics through plasma amino acid analysis. Anticancer Res 39(4):2035–2042. https://doi.org/10.21873/anticanres.13314
Uhlar CM, Whitehead AS (1999) Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem 265(2):501–523. https://doi.org/10.1046/j.1432-1327.1999.00657.x
Vaishnavi A, Capelletti M, Le AT, Kako S, Butaney M, Ercan D, Mahale S, Davies KD, Aisner DL, Pilling AB, Berge EM, Kim J, Sasaki H, Park S, Kryukov G, Garraway LA, Hammerman PS, Haas J, Andrews SW, Lipson D et al (2013) Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat Med 19(11):1469–1472. https://doi.org/10.1038/nm.3352
Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415(6871):530–536. https://doi.org/10.1038/415530a
Victorelli S, Passos JF (2017) Telomeres and cell senescence—size matters not. EBioMedicine 21:14–20. https://doi.org/10.1016/j.ebiom.2017.03.027
Voorneveld PW, Jacobs RJ, Kodach LL, Hardwick JC (2015) A meta-analysis of SMAD4 immunohistochemistry as a prognostic marker in colorectal cancer. Transl Oncol 8(1):18–24. https://doi.org/10.1016/j.tranon.2014.11.003
Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, Jatkoe T, Berns EM, Atkins D, Foekens JA (2005) Gene-expression profiles to predict distant metastasis of lymphnode-negative primary breast cancer. Lancet (London, England) 365(9460):671–679. https://doi.org/10.1016/S0140-6736(05)17947-1
Wang J-X, He Y-L, Zhu S-T, Yang S, Zhang S-T (2011) Aberrant methylation of the 3q25 tumor suppressor gene PTX3 in human esophageal squamous cell carcinoma. World J Gastroenterol 17(37):4225–4230. https://doi.org/10.3748/wjg.v17.i37.4225
Wang D, Yu X, Wang X (2016) High/positive expression of 5-fluorouracil metabolic enzymes predicts better response to S-1 in patients with gastric cancer: a meta-analysis. Int J Biol Markers 31(2):101–109. https://doi.org/10.5301/jbm.5000202
Wang P, Liang J, Wang Z, Hou H, Shi L, Zhou Z (2017a) The prognostic value of p53 positive in colorectal cancer: a retrospective cohort study. Tumor Biol 39(5):1010428317703651. https://doi.org/10.1177/1010428317703651
Wang S, Du H, Li G (2017b) Significant prognostic value of circulating tumor cells in esophageal cancer patients: a meta-analysis. Oncotarget 8(9):15815–15826
Wang L, Skotland T, Berge V, Sandvig K, Llorente A (2017c) Exosomal proteins as prostate cancer biomarkers in urine: from mass spectrometry discovery to immunoassay-based validation. Eur J Pharm Sci 98:80–85. https://doi.org/10.1016/j.ejps.2016.09.023
Wang X, Shi XQ, Zeng PW, Mo FM, Chen ZH (2018a) Circulating cell free DNA as the diagnostic marker for colorectal cancer: a systematic review and meta-analysis. Oncotarget 9(36):24514–24524. https://doi.org/10.18632/oncotarget.25314
Wang Y, Ji J, Wang B, Chen H, Yang Z, Wang K et al (2018b) Tumor-derived exosomal long noncoding RNAs as promising diagnostic biomarkers for prostate cancer. Cell Physiol Biochem 46(2):532–545. https://doi.org/10.1159/000488620
Wang H, Huang C, Yao X (2019) The functions of long non-coding RNAs in colorectal cancer. Transl Cancer Res 8(5):2192–2204
Warnecke-Eberz U, Metzger R, Miyazono F, Baldus SE, Neiss S, Brabender J et al (2004) High specificity of quantitative excision repair cross-complementing 1 messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer. Clin Cancer Res 10(11):3794. https://doi.org/10.1158/1078-0432.CCR-03-0079
Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM, Ullrich RT, Menon R, Maier S, Soltermann A, Moch H, Wagener P, Fischer F, Heynck S, Koker M, Schöttle J, Leenders F, Gabler F, Dabow I, Querings S et al (2010) Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2(62):62ra93. https://doi.org/10.1126/scitranslmed.3001451
Wenger CR, Beardslee S, Owens MA, Pounds G, Oldaker T, Vendely P, Pandian MR, Harrington D, Clark GM, McGuire WL (1993) DNA ploidy, S-phase, and steroid receptors in more than 127,000 breast cancer patients. Breast Cancer Res Treat 28(1):9–20. https://doi.org/10.1007/BF00666351
Werling RW, Yaziji H, Bacchi CE, Gown AM (2003) CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas. Am J Surg Pathol 27(3):303–310. https://doi.org/10.1097/00000478-200303000-00003
Wiedmann E, Baican B, Hertel A et al (1999) Positron emission tomography (PET) for staging and evaluation of response to treatment in patients with Hodgkin’s disease. Leuk Lymphoma 34:545–551
Wilcox CB, Baysal BE, Gallion HH, Strange MA, DeLoia JA (2005) High-resolution methylation analysis of the BRCA1 promoter in ovarian tumors. Cancer Genet Cytogenet 159(2):114–122. https://doi.org/10.1016/j.cancergencyto.2004.12.017
Wong NACS, Adamczyk LA, Evans S, Cullen J, Oniscu A, Oien KA (2017) A33 shows similar sensitivity to but is more specific than CDX2 as an immunomarker of colorectal carcinoma. Histopathology 71(1):34–41. https://doi.org/10.1111/his.13194
Wu M, Chang SC, Kampman E, Yang J, Wang XS, Gu XP et al (2013) Single nucleotide polymorphisms of ADH1B, ADH1C and ALDH2 genes and esophageal cancer: a population-based case-control study in China. Int J Cancer 132(8):1868–1877. https://doi.org/10.1002/ijc.27803
Xie H-W, Wu Q-Q, Zhu B, Chen F-J, Ji L, Li S-Q et al (2014) Long noncoding RNA SPRY4-IT1 is upregulated in esophageal squamous cell carcinoma and associated with poor prognosis. Tumor Biology 35(8):7743–7754. https://doi.org/10.1007/s13277-014-2013-y
Xing J, Ajani JA, Chen M, Izzo J, Lin J, Chen Z et al (2009) Constitutive short telomere length of chromosome 17p and 12q but not 11q and 2p is associated with an increased risk for esophageal cancer. Cancer Prev Res (Phila) 2(5):459–465. https://doi.org/10.1158/1940-6207.CAPR-08-0227
Yamamoto H, Shigematsu H, Nomura M, Lockwood WW, Sato M, Okumura N, Soh J, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Date H, Lam WL, Minna JD, Gazdar AF (2008) PIK3CA mutations and copy number gains in human lung cancers. Cancer Res 68(17):6913–6921. https://doi.org/10.1158/0008-5472.CAN-07-5084
Yang L, Francois F, Pei Z (2012) Molecular pathways: pathogenesis and clinical implications of microbiome alteration in esophagitis and Barrett esophagus. Clin Cancer Res 18(8):2138–2144. https://doi.org/10.1158/1078-0432.ccr-11-0934
Yang W, Han Y, Zhao X, Duan L, Zhou W, Wang X et al (2019) Advances in prognostic biomarkers for esophageal cancer. Expert Rev Mol Diagn 19(2):109–119. https://doi.org/10.1080/14737159.2019.1563485
Yao J, Huang JX, Lin M, Wu ZD, Yu H, Wang PC et al (2016) Microarray expression profile analysis of aberrant long non-coding RNAs in esophageal squamous cell carcinoma. Int J Oncol 48(6):2543–2557. https://doi.org/10.3892/ijo.2016.3457
Yarden Y, Pines G (2012) The ERBB network: at last, cancer therapy meets systems biology. Nat Rev Cancer 12(8):553–563. https://doi.org/10.1038/nrc3309
Ying M, Zhu XX, Zhao Y, Li DH, Chen LH (2015) KRAS mutation as a biomarker for survival in patients with non-small cell lung cancer, a meta-analysis of 12 randomized trials. Asian Pac J Cancer Prev 16(10):4439–4445. https://doi.org/10.7314/apjcp.2015.16.10.4439
Yoon HH, Catalano PJ, Murphy KM, Skaar TC, Philips S, Powell M et al (2011) Genetic variation in DNA-repair pathways and response to radiochemotherapy in esophageal adenocarcinoma: a retrospective cohort study of the Eastern Cooperative Oncology Group. BMC Cancer 11:176. https://doi.org/10.1186/1471-2407-11-176
Yoon DH, Ryu MH, Park YS, Lee HJ, Lee C, Ryoo BY et al (2012a) Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum. Br J Cancer 106(6):1039–1044. https://doi.org/10.1038/bjc.2012.47
Yoon HH, Shi Q, Sukov WR, Lewis MA, Sattler CA, Wiktor AE et al (2012b) Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with esophageal adenocarcinoma. J Clin Oncol 30(32):3932–3938. https://doi.org/10.1200/jco.2012.43.1890
Yoshida A, Kohno T, Tsuta K, Wakai S, Arai Y, Shimada Y, Asamura H, Furuta K, Shibata T, Tsuda H (2013) ROS1-rearranged lung cancer: a clinicopathologic and molecular study of 15 surgical cases. Am J Surg Pathol 37(4):554–562. https://doi.org/10.1097/PAS.0b013e3182758fe6
Young CD, Zimmerman LJ, Hoshino D, Formisano L, Hanker AB, Gatza ML, Morrison MM, Moore PD, Whitwell CA, Dave B, Stricker T, Bhola NE, Silva GO, Patel P, Brantley-Sieders DM, Levin M, Horiates M, Palma NA, Wang K, Stephens PJ et al (2015) Activating PIK3CA mutations induce an epidermal growth factor receptor (EGFR)/extracellular signal-regulated kinase (ERK) paracrine signaling axis in basal-like breast cancer. Mol Cell Proteomics 14(7):1959–1976. https://doi.org/10.1074/mcp.M115.049783
Yun YX, Wang YP, Wang P, Cui LH, Wang KJ, Zhang JY, Dai LP (2014) CYP1A1 genetic polymorphisms and risk for esophageal cancer: a case-control study in central China. Asian Pac J Cancer Prev 14(11):6507–6512. https://doi.org/10.7314/apjcp.2013.14.11.6507
Yurkovetsky Z, Skates S, Lomakin A, Nolen B, Pulsipher T, Modugno F, Marks J, Godwin A, Gorelik E, Jacobs I, Menon U, Lu K, Badgwell D, Bast RC Jr, Lokshin AE (2010) Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol 28(13):2159–2166. https://doi.org/10.1200/JCO.2008.19.2484
Zeidan BA, Townsend PA (2008) SELDI-TOF proteomic profiling of breast carcinomas identifies clinicopathologically relevant groups of patients similar to previously defined clusters from cDNA expression. Breast Cancer Res 10(3):107. https://doi.org/10.1186/bcr2107
Zeineldin R, Muller CY, Stack MS, Hudson LG (2010) Targeting the EGF receptor for ovarian cancer therapy. J Oncol 2010(414):676. https://doi.org/10.1155/2010/414676
Zeng M, Lv Y, Wang HF, Yiguli HA, Zhang JR, Yisikandaer A (2015) Correlation of CYP1A1 and GSTM1 gene polymorphisms and environmental factors to familial aggregation of esophageal cancer among the Kazakh ethnic group in Xinjiang. Genet Mol Res 14(4):19102–19109. https://doi.org/10.4238/2015.December.29.19
Zhang L, Farrell JJ, Zhou H, Elashoff D, Akin D, Park NH et al (2010) Salivary transcriptomic biomarkers for detection of resectable pancreatic cancer. Gastroenterology 138(3):949–957 .e941–947. https://doi.org/10.1053/j.gastro.2009.11.010
Zhang J, Zhao H, Gao Y, Zhang W (2012) Secretory miRNAs as novel cancer biomarkers. Biochim Biophys Acta 1826(1):32–43. https://doi.org/10.1016/j.bbcan.2012.03.001
Zhang YJ, Chen JW, He XS, Zhang HZ, Ling YH, Wen JH et al (2018) SATB2 is a promising biomarker for identifying a colorectal origin for liver metastatic adenocarcinomas. EBioMedicine 28:62–69. https://doi.org/10.1016/j.ebiom.2018.01.001
Zhao Z, Verma V, Zhang M (2015) Anaplastic lymphoma kinase: role in cancer and therapy perspective. Cancer Biol Ther 16(12):1691–1701. https://doi.org/10.1080/15384047.2015.1095407
Zhao S, Geybels M, Leonardson A, Rubicz R, Kolb S, Yan Q et al (2016) Epigenome-wide tumor DNA methylation profiling identifies novel prognostic biomarkers of metastatic-lethal progression in men diagnosed with clinically localized prostate cancer. Clin Cancer Res 23(1):311–319. https://doi.org/10.1158/1078-0432.ccr-16-0549
Zhao M, Mishra L, Deng C-X (2018) The role of TGF-β/SMAD4 signaling in cancer. Int J Biol Sci 14(2):111–123. https://doi.org/10.7150/ijbs.23230
Zheng H, Zhao Y (2015) Association of CYP1A1 MspI polymorphism in the esophageal cancer risk: a meta-analysis in the Chinese population. Eur J Med Res 20(1):46. https://doi.org/10.1186/s40001-015-0135-3
Zheng H, Wang Y, Tang C, Jones L, Ye H, Zhang G et al (2016) TP53, PIK3CA, FBXW7 and KRAS mutations in esophageal cancer identified by targeted sequencing. Cancer Genomics Proteomics 13(3):231–238
Zhu Y-Y, Yuan Z (2015) Pancreatic cancer stem cells. Am J Cancer Res 5(3):894–906
Zhuo ZG, Zhu YK, Deng HY, Li G, Luo J, Alai GH, Lin YD (2020) Predictive value of excision repair cross-complementation group 1 in the response to platinum-based chemotherapy in esophageal cancer: a meta-analysis. Oncol Res Treat 43(4):160–169. https://doi.org/10.1159/000505378
Zody MC, Garber M, Adams DJ, Sharpe T, Harrow J, Lupski JR, Nicholson C, Searle SM, Wilming L, Young SK, Abouelleil A, Allen NR, Bi W, Bloom T, Borowsky ML, Bugalter BE, Butler J, Chang JL, Chen CK, Cook A et al (2006) DNA sequence of human chromosome 17 and analysis of rearrangement in the human lineage. Nature 440(7087):1045–1049. https://doi.org/10.1038/nature04689
Zumoff B, Fishman J, Bradlow HL, Hellman L (1975) Hormone profiles in hormone dependent cancers. Cancer Res 35(11 Pt 2):3365–3373
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Janjua, K.A., Shahzad, R., Shehzad, A. (2022). Development of Novel Cancer Biomarkers for Diagnosis and Prognosis. In: Shehzad, A. (eds) Cancer Biomarkers in Diagnosis and Therapeutics. Springer, Singapore. https://doi.org/10.1007/978-981-16-5759-7_11
Download citation
DOI: https://doi.org/10.1007/978-981-16-5759-7_11
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-16-5758-0
Online ISBN: 978-981-16-5759-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)